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ABSTRACT
CAD is a large multifunctional protein catalyzing the initial three steps in de novo
biosynthesis of pyrimidine nucleotides in animals. Since pyrimidines are the building
blocks of nucleic acids and the precursors of other key macromolecular substances, the
up-regulation of CAD’s activity is essential for cell growth and proliferation, especially in
neoplastic cells. Thus, CAD has been considered an attractive target for the development
of anti-tumoral compounds. However, despite the central metabolic role and its thera-
peutic potential, due to the lack of knowledge about its organization and the structure
and function of its different enzymatic domains, no robust inhibitor that could be used
as anti-proliferative drug has been designed thus far. In this bachelor thesis, a research
study on CAD’s DHOase domain was conducted, particularly focused in understanding
the role of a flexible loop that appears to play a conserved catalytic role from E.coli to
humans. To examine the catalytic mechanism of this loop, a cloning approach was de-
signed to generate a human DHOase construct bearing the equivalent flexible loop of the
E.coli enzyme. This chimeric protein was expressed either in mammalian cells or in bac-
teria cultures and purified using different chromatographic techniques. Activity assays on
both the forward and reverse directions of the reaction were then performed in the chi-
meric huDHOase to estimate the turnover rate of the mutant. With a negligible enzymatic
activity (less than 2% of the wild type) the experiments here presented prove that, despite
having a conserved functional role, the flexible loop of E.coli and human DHOases are
not interchangeable. Overall, the results confirmed the implication of the flexible loop in
oligomerization and in the catalytic mechanism of DHOases, highlighting key differences
in the functioning of both mammalian and bacterial enzymes that will be exploited in
future work for the rational design of specific inhibitors against CAD.
Keywords: Biochemical analysis; Mutagenesis; Recombinant protein; Anti-tumoral
target
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Glossary
Ca-asp: carbamoyl aspartate
DHO: dihydroorotate
DHOase: dihydroorotase
dNTP: deoxynucleotide triphosphate
ecDHOase: E.coli dihydroorotase
FOA: 5-fluoroorotate
FPLC: fast performance liquid chromatography
GFP: green fluorescent protein
HDDP: 4-hydroxyphenylpyruvate dioxygenase
HPLC: high performance liquid chromatography
huDHOase: human dihydroorotase
huDHOase-ELF: human dihydroorotase with E.coli loop flexible
IMAC: immobilized metal affinity chromatography
MALS: multiangle light scattering
PALA: N-phosphonacetyl-l-aspartate
PCR: polymerase chain reaction
PEI: polyethylenimine
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEC: size exclusion chromatography
wt-huDHOase: wild type human dihydroorotase
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1. INTRODUCTION
1.1. Biological Background
1.1.1. Pyrimidine metabolism and CAD
Among the million of species on Earth, the human body dominates as the system that
comprises one of the most complex metabolic networks. Through an extensive number of
metabolic pathways —still under study—, human cells succeed on carrying out chemical
reactions crucial for its growth, proliferation and survivability every second. Among all
this highly regulated pathways, the chemical reactions leading the biosynthesis of purine
and pyrimidines nucleotides remain as some of the most challenging for research due to
its complexity and precedence.
Pyrimidines are heterocyclic compounds with two nitrogen atoms in its ring structure
from which several significant organic compounds are derived (Fig. 1.1) [1]. Although
these nitrogen bases might appear as basic and revisited, the attention to this type of
aromatic compound is such that NASA has lead projects that confirmed the presence
of non-terrestrial pyrimidines compounds in meteorites [2]. This discovery, a signific-
ant breakthrough for the study on life’s origin, did not go unnoticed by the scientific
community as pyrimidines constitute the compounds from which, among many others,
life’s building blocks are derived. Some of the nucleotides precursors that originate from
the biosynthesis of pyrimidines, like UDP-sugars and CDP-diacylglycerol diphosphatase,
are essential for cell functions like the assembly of cell membranes and the glycosyla-
tion of proteins. However, as hinted before, the attractiveness of their study comes from
pyrimidines —along with other heterocyclic aromatic organic compounds, purines— be-
ing the essential building blocks of crucial molecules like DNA (deoxyribonucleic acid),
RNA (ribonucleic acid) or vitamins [3].
Fig. 1.1. Skeletal formula of the pyrimidine ring and its nitrogen derivatives found in DNA
(Cytosine, Thymine) and RNA (Uracil)
Depending on their stage of development and type, cells obtain pyrimidines by two
1
distinct pathways [4]. On the one hand, by the salvage pathway, quiescent cells1 ob-
tain pyrimidines in an energy saving approach in which preformed bases and nucleosides,
coming from their degradative pathways, are recycled and used as intermediate molecules
for the generation of pyrimidines. On the other hand, by the de novo biosynthesis path-
way, pyrimidines are built from simpler raw molecules like bicarbonate, glutamine and
adenosine triphosphate (ATP) through a series of six enzymatic 2 steps highly conserved
among all species [5].
In animals, out of the six enzymatic steps for the de novo biosynthesis of pyrimidines,
the first three reactions are catalyzed by CAD, a 243 kDa multifunctional protein com-
posed by four enzymatic domains that self-assembles into hexamers3 of v1.5 MDa [6]
(Fig. 1.2). After Stark et al. described how the three last enzymatic domains remain co-
valently linked and act as a multifunctional protein [7], several studies have described its
architecture [6]; the biochemical mechanisms responsible for its behavior and control of
its constituents [6]; and, with contradictory results, the localization of CAD in the cell [5].
Fig. 1.2. Structural assembly of the proteins involved in the
synthesis of pyrimidines by the de novo pathway in
animal cells, yeast and E.coli. Adapted with permission
from Grande-García et al. [8]
Although CAD has been
reported to be present in
the nucleus during some
stages of the cell cycle [4],
it is widely accepted that
the complete four domain
construct remains mainly
in the cytosol associated
with the cytoskeleton net-
work outside of mitochon-
dria [5]. As shown in
Fig. 1.3, from bicarbonate,
glutamine and two ATP
molecules, the glutam-
inase (GLNase) and car-
bamoyl phosphate syn-
thase (CPSase-II) domains
catalyze the synthesis of
carbamoyl phosphate (CP),
the first product of the pathway. The next enzymatic domain, aspartate transcarbamoylase
(ATCase), channels the labile CP in its carboxyl terminal end inducing its reaction with
aspartate and giving carbamoyl aspartate (CA-asp) as product. Lastly, the fourth domain,
1cells halted in a non-dividing state
2produced by enzymes, molecular catalysts of living organisms
3protein formed by six protein subunits
2
the zinc metalloenzyme4 dihydroorotase (DHOase) placed between the CPSase and AT-
Case domains, catalyzes the reversible cyclization of carbamoyl aspartate to dihydrooro-
tate (DHO), the precursor of the pyrimidine ring [6].
Fig. 1.3. Chemical reactions taking place in the de novo pyrimidine biosynthetic pathway.
Adapted with permission from Grande-García et al. [8]
As CAD carries out the reactions of a high relevance pathway, it must be tightly
controlled in order to fit the requirements dictated by cells. By allosteric inhibition5
through uridine-5’-triphosphate (UTP) and activation by PRPP (phosphoribosyl 5’–pyro-
phosphate), the CPSase domain regulates the rate at which CAD catalyzes the products
of the pathway. In cases in which cells need to grow and proliferate, CAD up-regulates
its activity to satisfy the high demand of pyrimidines and its precursors, needed for the
synthesis of DNA and other cellular components. However, this up-regulation can also be
induced by a disease state like the development of neoplastic cells and tumors, in which
the need for rapid division translates into an aberrant use of the de novo pathway to syn-
thesize more pyrimidines [5].
Nevertheless, as any metabolic pathway, impairment of its control can lead to ma-
ladies. In the case of CAD, as this protein performs such a crucial function to cells, there
is only a small amount of documented non-fatal mutations in humans. This mutations,
however, are the focus of many studies [3] as they could provide with clues on the inter-
action between CAD’s enzymatic domains and the synergy of their functional roles [9].
1.1.2. DHOase, the lead character
Dihydroorotases (DHOases) are zinc metalloenzymes that take part in the pyrimidine bio-
synthesis by catalyzing the reversible cyclization of N-phosphonacetyl-l-aspartate (CA-
4enzymes that contain metal ions providing with some function
5negative modulation of a pathway in which a ligand binds to an active site of an enzyme to stop it from
functioning
3
asp) to dihydroorotate (DHO) [10]. The hydrolytic cleavage of DHO is favored at pH 8.0
while the cyclization of CA-asp in the forward reaction is optimal at pH 5.5
By phylogenetic analysis, gene duplication justify the existence of two types of DHOases
that have diverged from the same ancestor. Type I DHOases are the most ancient and lar-
ger (approx. 45 kDa) and appear covalently linked to other proteins or assembled as
enzyme domains of other multifunctional proteins [11]. This is the case of the DHOases
found in mammals and Gram-positive bacteria, among others. On the other side, type II
DHOases are more recent in the evolutionary scale and present a smaller size (approx.
38 kDa). Type II DHOases appear as monofunctional enzymes that do not interact with
the rest of the enzymes of the pyrimidine pathway and present major differences in their
sequence with respect to type I [12]. These DHOases are the ones present in eubacteria
like E.coli, fungi and plants [8].
While members of the same type of DHOases share more than 40% of its sequence
identity, when comparing both types, the major changes type II have undergone trans-
lates into less than 20% of sequence identity [11]. However, both types belong to the
amidohydrolase superfamily, a family of hydrolytic enzymes6 that share the same folding
conformation, the TIM-barrel. This structural framework consists of eight α-helices7 and
eight parallel β-strands8 that alternate along the peptide backbone forming a solenoid that
curves around to close on itself [10].
Depending on the species, DHOases carry different number and types of metal centers;
and when this native metals are substituted by Cd2+ Co2+ and Mn2+, conservation of the
catalytic activity is observed. Some studies, by alignment of DHOases sequences between
different species, have provided with further identification of the conserved residues that
are more likely to be in charge of acting as bridging ligands9 between the metal cations
due to its properties [10]. Nevertheless, the variability around the assembly and number
of metals atoms present in the DHOases, is a potential target of study for the design of
species-specific inhibitors for this type of enzymes [13].
1.1.3. E.coli DHOase
In E.coli, the DHOase is a homodimeric10 enzyme of 76 kDa and 694 amino acids [10].
The crystallization work of Lee et al. confirmed the structure of this DHOase. With two
identical subunits, each of them folds in a TIM-Barrel conformation (8 parallel β-sheets
6enzymes that speed up the hydrolysis of a chemical bond
7motif in a protein in which its polypeptide chain coils into a spiral shape
8protein motif in which the polypeptide chain shows a streched and sheet-like shape
9ligands that connects two or more atoms
10protein made by two identical proteins
4
flanked by 8 α-helices at its outer surface) and presents binuclear zinc centers with both
metal ions separated by ∼3.5 Å (Fig. 1.4). In both subunits the zinc atoms are coordinated
by histidine and aspartate residues. On subunit I, a carbamate functional group (coming
from a post translational modification of a lysine), a water molecule, and the DHO product
lying close in the active site11 pocket, bridge the active metals. However, for subunit II,
in addition to the carboxylate lysine, one of the carboxylated groups of the CA-asp mo-
lecules is also in charge of connecting the zinc atoms [12].
The solved structure for E.coli DHOase published by Thoden et al., crystallized in
the presence of racemic12 substrate (D,L-CA-asp), shows the substrate CA-asp bound to
subunit II by its active site, while the active site of subunit I is occupied by DHO [10].
Considering this odd and unusual placement of different ligands in each subunit, Lee et
al. crystallized the enzyme in the presence of only DHO, the product. The crystal unex-
pectedly showed the same arrangement previously reported, a CA-asp bound to the active
site of subunit II while DHO occupied subunit I [13]. To explain this phenomena the
authors theorized that, by changes in three pairs of residues close to the dimer interface,
each subunit may communicate with the other about its content. However, they also dis-
covered that, even with different ligands in their active sites, the coordination number of
the zinc atoms is identical appearing closer to each other only in subunit I [13].
Fig. 1.4. Top view in cartoon representation of ecDHOase showing its characteristic TIM-Barrel
conformation and its binuclear zinc center. α-helices are in green, β-sheets in red and
the bridging ligands of the two zinc atoms, depicted as blue spheres, are shown in
ball-and-stick representation [PDB ID code 1XGE].
11region of an enzyme which carries out a chemical reaction when a ligand binds to it
12composed by enantiomers of a chiral molecule in equal proportion
5
1.1.4. The first sighting of a flexible loop
Nonetheless, the most important discovery derived from the ecDHOase crystals analyzed
by Lee et al. in 2005 consisted on the sighting of a particularly important structure, a
flexible loop (annotated as the 4th loop in the 3D model structure) comprised by 11 amino
acids (residues from 105 to 115). This loop appears in a different conformation for each
subunit of the DHOase from E.coli. In the case of subunit II, the loop is a IN conforma-
tion: the whole structure reaches and curls towards the active site and the two residues at
the tip of the loop make hydrogen bonds with the bound substrate CA-asp. Per contra, in
subunit I, the loop appears in a OUT conformation: no interaction between the loop and
the bound product DHO is observed and the loop belongs to the protein surface, facing
away from the active site leaving it solvent exposed [12].
This peculiar loop in/loop out mechanism, similar to the movement of a hinge, would
explain the catalytic activity of the enzyme as follows [12]:
1. CA-asp starts its cyclization by making direct molecular contacts with the binuclear
zinc center of one active site. Due to these metal cations, the C5 of the CA-asp
becomes more electrophilic promoting bond formation.
2. The flexible loop comprising residues from 105 to 115 reaches towards the active
site inducing a hydrogen bond interaction between Thr109 and the CA-asp. This
promotes the optimal and stable confinement of the substrate into the binding site
pocket, avoiding its interaction with any water molecule.
3. As now the C4, O4 and O5 of the CA-asp are no longer a carboxylate group but
a carbonyl one in DHO, those no longer can act as bridging ligands for the zinc
atoms at the active site and causes the DHO molecule to shift its position moving
upwards.
4. The movement of DHO away from the active pocket causes pressure on residue
Thr109 forcing the loop to adopt its open conformation and leaving the active site
cavity filled with water molecules.
Furthermore, this hinge movement happening in both active sites of the protein, could
be the source of the communication observed between subunits [12]. The excluding of
water molecules during the IN conformation and the additional conformational changes
happening in the side-chains closer to the loop at the dimer interface, are theorized to
cause the asymmetry and communication of both subunits mediating a positive cooperati-
vity with respect to DHO.
6
Fig. 1.5. Side view in cartoon representation of ecDHOase showing its flexible loop in yellow,
alpha helices are in green, beta sheets in red and the bridging ligands of the two zinc
atoms, depicted as blue spheres, in ball-and-stick representation [PDB ID code 1XGE].
1.1.5. huDHOase and its flexible loop
As mentioned before, the human DHOase exists in the cell assembled to other enzymes
creating the multifunctional protein CAD. Thanks to the work of Grande-García et al., the
structure of the huDHOase has been solved and shows interesting features that set them
apart from the other species studied DHOases.
Firstly, the huDHOase, analogous to the other enzymes belonging to the amidohydro-
lase superfamily, presents a TIM-barrel folding conformation with eight parallel β-strands
connected by eight outer α-helices. However, unlike the ecDHOase, the β-strands of the
huDHOase are also connected by a smaller domain composed by residues from the N-
terminal13and C-terminal13 , the latter crucial for protein solubility [8].
Fig. 1.6. Cartoon representation of huDHOase showing the two loop conformations, its Zn2+ in
sphere shape and the coordinating elements in ball-and-stick representation [PDB ID
code 4C6C]. Adapted with permission from Grande-García et al. [8]
13termini of a protein, N stands for the initial free amine group of the chain and C for the carboxyl group
of the last amino acid of the chain
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Regarding its active site, huDHOase (Fig. 1.6) presents a cavity-shaped binding pocket
with a major singularity, the presence of three Zn2+ ions (Zn-α, Zn-β, Zn-γ). While the
Zn-α and Zn-β exhibit their configurations and bridging ligands being identical to the
ecDHOase, for the case of Zn-γ its localization has been reported deep into the β-strands
of the barrel coordinated by several residue side chains and a water molecule, and con-
nected to the Zn-α by a histidine side chain [8].
In spite of the sequence divergence among the two DHOases, both the human and
E.coli DHOases maintain a similar architecture and perform its catalytic activity following
an analogous approach. By binding of CA-asp to Zn-α and Zn-β through it β-carboxylate
group (C4, O4, O5), the two metal cations induce the nucleophilic attack by the N3 atom
of the substrate (Fig. 1.3). A proton from this nitrogen is then transferred to O5, which is
released as an hydrogen ion, and the bond between C4 and O5 is cleavaged to make the
product DHO. For the reverse reaction, as the O4 of the recently generated DHO keeps
its bond to Zn-β, this would facilitate the polarization of the C4 and O4 bond making
it vulnerable to another nucleophilic attack from the bridging hydroxide ion, leading the
catalysis of the substrate in the reverse direction [8].
Once the substrate is bound to the active site, the flexible loop comprised by residues
1561-1569 curls towards the substrate (loop IN) and a threonine (Thr1562) interacts with
CA-asp stabilizing its conformation and closing the binding pocket avoiding any interac-
tion of the transition state with water molecules. Once the DHO is formed, the loop adopts
its OUT conformation due to the upwards displacement of the product which forces it to
move in a hinge fashion, letting the active site exposed to the rest of the water molecules
and disassembling its interactions with the ligand and active site [8].
Fig. 1.7. Cartoon representation of huDHOase flexible loop showing the IN conformation in
yellow and OUT conformation in orange. The Zn2+ are shown as spheres and the
residues responsible of key interactions are labelled. Adapted with permission from
Grande-García et al. [8]
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In the case of huDHOase, studies on the pH dependency of both the forward and re-
verse catalytic reactions were done following previous experiments performed on Mus
musculus DHOase [14]. The ionization of the bridging water, and its decrease in pKa
when binding to the metal atoms, translates into two different pKa for huDHOase: 8.3
in the forward direction and 7.1 for the reverse reaction. These pH variations experi-
ments also demonstrated that, although the Zn-γ does not influence the overall enzyme
structure, its binding (dependable on pH conditions) affects the activity of the enzyme [8].
1.2. State of the Art
1.2.1. Studies done by mutating ecDHOase and huDHOase
Extensive study has been done on ecDHOase by mutating isolated residues in order to
determine the effect the mutations had on its structure and function. Lee et al. performed
two single-point mutations that altered the interaction between Thr109 and Thr110 with
the substrate CA-asp [11]. These two residues, besides being involved in the binding
of the substrate through hydrogen bonds, are also responsible for the stabilization of the
enzyme’s transition state. When mutations into Ser/Val/Ala/Gly were performed on this
two residues, negligible activity was obtained. The rationale behind this result was hy-
pothesized by looking at the crystal structures of the mutants. Despite the absence of a
significant change in the overall 3D conformation of the protein, the spatial configuration
of the flexible loop and its vicinity appeared altered. The substrate, unable to bind by
hydrogen bonds to these two residues due to the mutation, prevented the enzyme from
closing the loop and catalyze the product. One one side, Thr109 was hypothesized to
contribute in enhancing substrate affinity, while Thre110 could be responsible of subtrate
binding. Furthermore, by deletion of the whole flexible loop (residues from 107 to 116)
ecDHOase mutants were assayed and no activity was observed. Therefore, although non-
directly, the flexible loop was proposed as one of the key elements of the enzyme that
would mediate catalysis by enhancing the affinity for the substrate and the stability of the
transition state [11].
Aside from the results, in their methodology Lee et al. described the use of the
QuikChange Site-directed Mutagenesis14 kit from Stratagene for the mutations of the
residues using a pBS+ plasmid15 with ecDHOase as template. To purify the protein, after
being produced by expression in E.coli strain X7014a, the lysate of the cells was subjec-
ted to thermal denaturation and MonoQ ion exchange columns and Microsep centrifugal
devices were used for the purification and concentration of the protein. For the activity
14procedure in which the genetic material of an organism is changed
15circular DNA strand that is present in bacteria cytoplasm and replicates separately from its chromo-
somes, used extensively for the manipulation of genes in the laboratory
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assays, spectophotometric measures at 230 nm following the formation of product DHO
were performed in 96-well plates, and the reaction was triggered by the addition of the
mutant enzymes by a Mosquito nanoliter liquid handling robot [11].
Regarding huDHOase, several mutations reported by Grande-García et al. aided in
a preliminary hypothesis on the structures and functional groups crucial for the protein
dimerization, the binding of the zinc atoms and its catalytic function. Moreover, residues
of the human flexible loop were mutated following the results obtained from Lee et al.
[11] to test their relative activity. The mutations of T1562 and F1563 (residues equivalent
to Thr109 and Thr110 in EcDHOase) into Ala showed once again the inactivation of the
enzyme (Fig. 1.8). This could support the hypothesis describing the flexible loop as an
essential component for the catalysis. However, no further mutations that could possible
unravel new interactions between the flexible loop and the ligand in the binding pocket
were performed [8].
Fig. 1.8. Relative activity of the mutant huDHOases performed by Grande García et al. showing
almost no activity for the mutations correspoding to the flexible loop. Adapted with
permission from Grande-García et al. [8]
The methodology followed by Grande-García et al. also included the use of the
QuikChange Site-directed Mutagenesis for the point mutations of the huDHOase. The
plasmid taken as template, in this case, was pOPIN-M and the cells used to express the
plasmid, HEK293S-GnTI-. To purify the protein obtained, Ni2+ HisTrap Chelatin FF and
HiTrap SP HP columns (GE Healthcare) were used before a last step consisting of size-
exclusion chromatography with a Superdex 200 10/300 column (GE Healthcare). Once
the protein was purified, they employed a 10 kDa cut off membrane of the Amicon Ul-
tra system. In the case of the activity assays, a colorimetric approach was adopted in a
96-well plate in which the formation for product DHO was quantitatively measured fol-
lowing its absorbance at 230 nm [15].
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1.2.2. Studies on CAD’s possible inhibitors
The search for a molecule able to bind to any of CAD’s enzymatic domains in order to halt
the de novo pathway of pyrimidine biosynthesis started with Collins and Stark in 1971.
These two scientists, after an extensive study on the ATCase structure, synthesized PALA
(N-phosphonacetyl-l-aspartate, seen in Fig. 1.9) a synthetically designed molecule with
high potential as a stable inhibitor of ATCase [7].
Fig. 1.9. Skeletal formula of N-phosphonacetyl-l-aspartate (PALA),
an ATCase inhibitor [7].
PALA is an ana-
logue molecule of the
transition state, a tetra-
valent hydrophobic mo-
lecule that is suscept-
ible to cellular uptake
by fluid phase endocyt-
osis16. It was designed
with structural features
from both substrates of
the ATCase in order to
robustly bind in the act-
ive site and leave the enzyme halted in a conformation similar to the one established
during the transition state [16]. Studies on its efficiency report a binding strength 1000
times higher than the binding strength of substrate carbamoyl phosphate and its ability to
block the proliferation of a homogeneous solution of cells in vitro by its administration
on a high dose [17].
On clinical trials, the most important evaluation for the anti-tumoral drug PALA
showed inhibition of 16-72% of the ATCase activity in tumor and normal tissue, thus
inhibiting the de novo pathway of pyrimidine biosynthesis [17]. What is more, upon
restoration of the pathway by removal of PALA, no pyrimidine synthesis was observed
indicating an unexplained prolonged retention of its effect by the cells [18].
On the other side, all in vivo assays in tumor tissue showed also how the pyrimidine
metabolic behaviour of cells vastly depends on the dose administered and, even when the
maximum tolerated dose was administered, PALA is not able to decrease the pool pro-
duction of UTP and CTP to the extent of completely inhibiting the de novo synthesis.
However, one of the most promising observations coming from this studies, is the abil-
ity of PALA to selectively affect only the tumor tissue while sparing the rest of healthy
cells. Consequently, as malignant cells have limited survival ability under such adverse
16process in which cells internalize external matter bound to vesicles into its cytoplasm by energy ex-
penditure
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condition, PALA would aid in the delay of the tumor growth and mean survival time if
combined with other anti-tumoral drugs as its use as a single therapeutic strategy does not
show promising results [17].
Regarding the DHOase, a particularly interesting study done in 2007 by Lee et al.
[19] presented their discoveries on ecDHOase as a precedent of possible research on the
DHOase from the Plasmodium species, parasites involved in malaria disease. These four
types of Plasmodium responsible for the disease present 6 different enzymes to synthesize
pyrimidines through the de novo pathway and are unable to carry out the salvage path-
way, limiting its resources of pyrimidines from the de novo pathway. This revelation
could open a new line of research in the future [19]. If the DHOase from this Plasmodium
has a custom-built structure or a different catalysis action, then specific inhibitors against
this DHOase (sparing the huDHOase) could be synthesized and be tested as a possible
treatment against malaria.
In the case of ecDHOase and huDHOase, 5-fluoroorotate (FOA) has been used as a
product-like inhibitor in the crystallization work of Lee et al. and Grande-García et al. to
study the interactions of this molecule with the active site. Precluding the enzyme from
hydrolyzing this inhibitor, the conformation of the ecDHOase and huDHOase flexible
loop stayed with and OUT conformation, leaving FOA bound in the active site. However,
the use of this product-mimic in both studies is only limited to enable the formation a
stable tetragonal crystal structure for the crystallization of the proteins [8] .
To test the power of FOA as inhibitor of Plasmodium DHOase, the study by Gomez
and Rathod [20] presented data on the effectiveness and toxicity of this inhibitor on mal-
aria infected mice. With a dose dependent administration of FOA, infected mice showed
no sign of parasitemia in the case of the higher dose (5 mg/kg). Despite this good result,
several mice died in the process, not from the disease, but from the toxicity of this dose.
To counteract this, uridine was administered to the mice in order for the huDHOase to
synthesize pyrimidines by the salvage pathway. These mice, with both a high dose of
FOA and an additional administration of uridine, were cured of the malaria and did not
present any adverse effect related to the toxicity of the inhibitor [20].
The last inhibitor for huDHOAse proposed to date is an ester variation of HDDP
(Fig. 1.10), 4-hydroxyphenylpyruvate dioxygenase, a derivative of of pyrimidine-4-carbo-
xylic acid created by Christopherson et al. [21]. Although no clear description on the
transport mechanism has been described yet, when tested in human leukemia samples,
promising results were obtained. No cytotoxicity was observed on both mouse and human
leukemia grown in culture. With no major perturbation in the intermediates of the nucle-
otide metabolism, at a concentration of 250 µM it induces the death of human CCRF-CEM
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leukemia cells [22]. However, as promising as this might sound, the results presented by
the authors were not obtained as a consequence on the halting of the de novo biosynthesis
pathway. Inhibition of the DHOase was not observed and the administered HDDP-variant
affected the cells by inhibiting their cycle progression from late G2 or M phase to G1
leading the inhibition of their growth [22]. Besides HDDP and its variants, no other feas-
ible inhibitor against huDHOase has been proposed for experimentation in vivo which, in
combination with PALA, could allow a superior performance in the blockage of the de
novo pathway.
Fig. 1.10. Skeletal formula of HDDP ester variant, a possible inhibitor for huDHOase [22]
1.3. Regulatory Framework
The experimental work performed for the accomplishment of this project was all done un-
der the regulations concerning the chemical and biological practice European and Spanish
Royal Legislative Decrees dictate.
Royal Decree 665/1997, eventually modified in R.D 1124/2000, provides the direct-
ive to follow during the manipulation, storage and transportation of the chemical reagents
used in this project for the mutagenesis and chromatography procedures. Moreover, ac-
cording to the Centro de Biología Molecular Severo Ochoa (CBMSO)’s requirements,
β-mercaptoethanol, acrylamide and other special chemical compounds were treated with
particular care to comply with the articles drawn up attending the prevention of risks de-
rived from the use of chemicals, as well as the restrictions applied on their management.
Furthermore, the Royal Decree 833/1988, modified later in R.D 952/1997, establishes
the regulation that must be taken into account when managing heavy metals and their
treatment to ensure the protection of the of human health, the protection of the environ-
ment and the preservation of the natural resources. As in this project nickel was used, its
storage and processing was approached by compliance of both the Royal Decree and the
CBMSO’s chemical residues policy.
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As cell culture related practices were performed in a Biosafety Level 2 (BSL-2) labor-
atory, this working environment is regulated by some postulates in the frame of the Royal
Decree 664/1997 for the protection of workers against the biological risks related to the
exposure to biological agents. Firstly, for the grant access of the BSL-2, a mandatory
training curse conducted by the CBMSO for the correct use of its facilities was under-
taken. Good practice for the minimization of the liberation of the biological agents, along
with its storage and evacuation and the personal hygiene when exposed, were followed
to comply with both the CBMSO policy and consequently, with the Spanish legislation.
However, despite mutating the sequence of a protein by cloning techniques and producing
the protein in cells, no special additional regulations are involved for this part of the pro-
ject as the article 1 of the Royal Decree 178/2004 for the handling of mutated biological
organisms determines as exception this type of mutagenesis in vivo.
Although Biotium (the manufacturer of the nucleic acid gel staining GelRed) conduc-
ted several tests with three independent testing services to determine the non-mutagenic
and non-cytotoxic character of the dye, as the working conditions in the CBMSO involved
the use of equipment handled by other groups that did not use GelRed but Ethidium Brom-
ide (EtBr) or other carcinogenic dyes, the procedures performed in this project followed
the requirements for safety and health protection against carcinogenic agents prescribed
by the Directive R.D 665/1997. This Royal Legislative Decree, modified later in R.D
1124/2000, formulates the regulations laboratory personnel must follow when handling
or being exposed to carcinogenic agents. In the frame of the work done in this project,
several approaches for the safety of both the student and the rest of CBMSO personnel
were adopted in accordance to articles 4, 5 and 6. By using GelRed instead of EtBr the
project abided by article 4 that seeks for the use of less dangerous substitutes, article 5
(Prevention and Reduction of Exposure) was guaranteed with the special treatment of the
gels after its use in a separate container for its eventual processing, and finally for article
6 personal hygiene and action lines for the individual protection were followed with the
use of gloves and coat.
Finally, the handling of the non-chemical, non-biological and non-carcinogenic residues
derived by the laboratory work, was followed by the Law 5/2003 of the Autonomous
Community of Madrid and the measures for the occupational health and safety of the
laboratory personnel were applied in accordance with Law 54/2003.
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2. MOTIVATIONS AND OBJECTIVES
As mentioned in the introductory section of this work, impairment of the complex hu-
man metabolic network causes numerous diseases. But, from Alzheimer [23] to Hunting-
ton’s disease [24], enzyme inhibitors that handicap abnormal enzyme’s catalytic activity
have proven to be a feasible alternative in increasing the efficacy of current therapies or
becoming the only therapeutic regime in the future.
Regarding cancer, the heterogeneity of this disease along with current studies en-
visaging it as one of the lead causes of death in the next decades [25], are two powerful
incentives in the motivation for this project, as both encourage the search for alternative
treatments to the traditional cytotoxic procedures like chemotherapy and radiotherapy.
Therefore, by using the current progress molecular biology has exhibited in the last years,
stratified medicine and personalized strategies for patients are the two interests engaging
in the battle against the large amount of different types of cancer.
Furthermore, with the modest research done on human CAD and its domains, every
study on its structure or activity is an additional step towards the complete understanding
of human’s pyrimidine synthesis pathway. And, once the key elements of the pathway are
determined, the discovery of new approaches to halt it will follow.
With that being stated, three main motivations leaded the study of huCAD’s DHOase
domain:
• The need to transfer to academia data about huDHOase’s elements in order to find
its weaknesses and vulnerabilities as enzyme.
• The demand from pharmaceutical companies on better inhibitors for the huDHOase
domain.
• The search for an alternative/additional anti-tumoral treatment to fight cancer.
Motivated by those three catalysts, the objectives set in this project for the accom-
plishment of at least the first one are:
1. To design and choose the best experimental strategy to enable the cumbersome
mutation of the flexible loop of huDHOase into the flexible loop from ecDHOase
in a plasmid.
2. Express the plasmid in mammalian cells and produce the protein.
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3. Purify the protein by selecting the proper chromatography techniques.
4. Test experimentally, by activity assays, the catalytic activity of the new mutant:
huDHOase-ELF.
5. Draw conclusions on the key elements of huDHOase sequence responsible on its
catalytic function.
6. Propose techniques and procedures needed to solve the possible problems encountered
during the project and present the future work required to continue the study on
huDHOase.
Ultimately, as shown in Fig. 2.1, the main goals of the project were the successful
completion of 4 experimental objectives that could then generate the data needed to ana-
lyze the mutations’ repercussions and their significance.
Fig. 2.1. Diagram of the experimental goals set for the project.
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3. MATERIALS AND METHODS
In this chapter, the main procedures performed to reach the goal proposed are presen-
ted in separate sections in which innovative approaches, and common experimental pro-
tocols, are explained. For the sake of clarity, a short description of the workflow is as
follows:
I. Linearization, by digestion with restriction enzymes, of the circular plasmid pOPIN-
M-huDHOase that contains the huDHOase (needed as template for the cloning pro-
cedure) and other important features (6xHis tag, MPB protein and PS site) for the
future purification of the mutant portein.
II. Once a set of primers17 was designed and prepared, as the sequence selected to be
mutated was remarkably long, the cloning step was divided into 4 rounds of separate
and consecutive mutagenesis protocols with a pair of mutagenic primers for each
round. In the first and last rounds, one mutagenic strategy was performed (The
Three PCRs Method) while in the second and third rounds a completely different
approach was taken (QuikChange Site-directed Mutagenesis).
III. After each round of mutagenesis, the plasmids containing the gradually mutated
huDHOase sequence were verified by NaeI digestion and sequencing so cloning
could continue progressively with the confirmation that the mutations were present.
IV. To produce the mutant huDHOase-ELF in a high throughput manner, transfection of
mammalian cells with the final mutated plasmid was performed with polyethylen-
imine18 (PEI).
V. To isolate the protein of interest from the rest of proteins produced by the cells,
purification was accomplished using IMAC19 (Immobilized Metal Affinity Chroma-
tography) and SEC20 (Size Exclusion Chromatography).
VI. Finally, to assess the functionality of the purified mutated protein, activity assays
were carried out on both the wild type huDHOase and chimeric huDHOase-ELF to
examine the effects the mutations had on its catalytic activity.
17short DNA strand that provides with a starting point to the DNA polymerase for the synthesis of DNA
18non-viral vector used in the transfection of nucleic acids into cells
19chromatography technique that separates proteins by their different affinity to metal ions
20chromatography technique in which molecules are sorted by size due to their different efficiency pen-
etrating the pores of the stationary phase inside a column
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3.1. Cloning of huDHOase
3.1.1. huDHOase-pOPIN-M plasmid digestion
In this project, a special construction of the plasmid pOPIN-M (Oxford Protein Produc-
tion Facility) was used. This plasmid consisted of the wild type human DHOase sequence,
a PreScission Protease cleavage site, an ampicillin resistance gene and the sequences cod-
ing for the maltose binding protein (MBP) and a tail of histidines (6xHis tag) (Fig. 3.1).
Any of these features, essential components needed to perform the cloning, transforma-
tion and purification protocols.
To digest the circular plasmid pOPIN-M-huDHOase for further use in the In-Fusion
Reaction, restriction enzymes were used to cut the double stranded genetic material into
a linear strand. For that, a reaction mix with 1662.5 ng/µl plasmid pOPIN-M-huDHOase,
NEBuffer 10X (New England Biolabs), BSA 100X (New England Biolabs) and MilliQ
water was prepared and, separating this mix in different tubes, one type of restriction en-
zyme (either HindIII or KpnI from New Englad Biolabs) was added in a 1:0.2 relation (µg
of Plasmid:Units of enzyme). After incubation at 37ºC for 3 hours to assure the correct
linearization of the vector, the aliquots were kept frozen at -20ºC until their further use.
Fig. 3.1. Map of wild type huDHOase in pOPIN-M.
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3.1.2. Primer design and preparation
To start the mutation process, the nucleotides conforming the flexible loop from human
DHOase were first analyzed (their implication in dimer formation, localization, type, etc.)
and several of them were chosen to be mutated in the cloning procedure. In this case, the
sequence mutated was 11 amino acids in length and belongs to the flexible loop domain
of each subunit of the huDHOase homodimer.
The total amount of 33 nucleotides were mutated in what will be addressed as rounds.
In each round, a different pair of primers (one primer for the direct elongation d and
another for the reverse r) were used to mutate and insert the desired bases. The aim be-
hind their sequence design containing the sought mutations was for the DNA polymerase
to elongate them in a polymerase chain reaction (PCR)21 ultimately creating copies of
mutated DNA chains.
The design of those primers was done taking into account both the target sequence
(human) and the one pursued (E.coli):
Human DHOase flexible loop L N E - T F S E L - R L D
E.coli DHOase flexible loop P A N A T T N S S H G V T
As indicated in Table 3.1, for the first round, the first three amino acids (L N E)
were mutated into the first three of the E.coli sequence (P A N). In the second round, the
previous DNA sequence was used to continue the transformation into E.coli’s loop with
an insertion of Alanine and the mutation of the next two amino acids into Threonine-
Threonine. For the third round, by taking the sequence coming from round 2 as template,
the three consecutive amino acids of the huDHOase were mutated into Asn-Ser-Ser. Fi-
nally, in the fourth round, the previous mutated DNA was used as template again and an
insertion of Histidine and the mutation of the next three amino acids was performed (H G
V T).
Amino acids targeted in huDHOase for mutation Amino acids of E. cDHOase inserted in the primer Primer Pair
CTC GCC AAC CCC GCC AAC MR-mut1-d
Mutagenesis Round #1
L N E P A N MR-mut1-r
ACC TTC GCC ACC ACC MR-mut2-d
Mutagenesis Round #2
T F A T T MR-mut2-r
TCT GAG CTG AAC AGC AGC MR-mut3-d
Mutagenesis Round #3
S E L N S S MR-mut3-r
CGG CTG GAC CAC GGC GTG ACC MR-mut4-d
Mutagenesis Round #4
R L D H G V T MR-mut4-r
TABLE 3.1. TARGET SEQUENCES AND MUTATING BASES
COMPRISING THE CENTRAL PART OF EACH PRIMER PAIR
21laboratory technique used to generate millions of copies of a template DNA strand
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Mutagenesis in consecutive rounds was possible due to the architecture given to the
primers, and their peculiar attachment to the target sequence in the annealing22 step of
a polymerase chain reaction. As seen in Table 3.2, primers that will be used to mutate
huDHOase flexible loop have two distinct constituents. On one side, two extremities,
represented in green color, were incorporated in the primer as they are complementary
to the bases of the target huDHOase and will anneal to this sequence when subjected to
the right temperature in a PCR. On the other side, represented in red color, the mutating
bases that will give rise to the ecDHOase loop are integrated in the middle and, although
they won’t anneal to the target sequence, the stretch of these bases will remain in place
thanks to its bound extremities. In this way, when a PCR reaction takes place, the DNA
polymerase23 will start attaching nucleotides to these primers until the rest of the template
is completely copied, creating a mutated chain due to the presence of the ecDHOase bases
(coming from the middle of the primers) in the final sequence.
Table 3.2 also includes the specifications of DHOd and DHOr3. For these two primers,
blue bases correspond to complementary nucleotides of the plasmid pOPIN-M while
green colored bases represent the complementary to the huDHOase initial and final se-
quences.
Furthermore, to avoid the formation of secondary structures in the primers that would
prevent them from properly annealing into the template sequence during PCRs, the melt-
ing temperature was taken into account and only the primers with the lowest melting
temperate were chosen [26].
Primer name Length Mw (g/mol) Tm (ºC) Sequence of Primers 5’-3’
MR-mut1-d 39 11880 70.2 GGG CTG AAG CTT TAC CCC GCC AAC ACC TTC TCT GAG CTG
MR-mut1-r 39 12098 70.2 CAG CTC AGA GAA GGT GTT GGC GGG GTA AAG CTT CAG CCC
MR-mut2-d 39 11786 73.7 CTT TAC CCC GCC AAC GCC ACC ACC TCT GAG CTG CGG CTG
MR-mut2-r 39 12195 73.7 CAG CCG CAG CTC AGA GGT GGT GGC GTT GGC GGG GTA AAG
MR-mut3-d 39 11927 75.4 GCC AAC GCC ACC ACC AAC AGC AGC CGG CTG GAC AGC GTG
MR-mut3-r 39 12055 75.4 CAC GCT GTC CAG CCG GCT GCT GTT GGT GGT GGC GTT GGC
MR-mut4-d 43 13209 74.2 ACC ACC AAT AGC AGC CAC GGC GTG ACC AGC GTG GTC CAG TGG
MR-mut4-r 43 13243 74.2 CCA CTG GAC CAC GCT GGT CAC GCC GTG GCT GCT ATT GGT GGT
DHOd 41 12576.2 68.6 AAG TTC TGT TTC AGG GCC CG A TGA CCT CCC AAA AGC TTG TG
DHOr3 37 11477.5 64.3 ATG GTC TAG AAA GCT TTA ATC AGG AAG CCC TGG GAT G
TABLE 3.2. FEATURES OF THE PRIMERS DESIGNED
After purchasing the primers from Sigma-Aldrich, they were all prepared in a 20 µM
concentration by resuspending them in TE 1X pH 8 (10mM Tris-HCl, 1mM EDTA) and
22pairing attachment of complementary bases on two single stranded DNA sequences through hydrogen
bonds to create a double stranded sequence
23enzyme that synthesize DNA by adding nucleotides to a pre-existing short nucleotide strand already
annealed to the template
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incubating them 10 minutes for hydration.
3.1.3. The Three PCRs Method
For the first and fourth round of mutagenesis the Three PCRs Method was used. The
name given to this procedure comes from the fact that three polymerase chain reactions
(PCRs) must be performed to successfully complete one round of mutagenesis. A PCR
is a procedure used in molecular biology in which a strand of DNA can be amplified to
obtain million of copies, due to the ability of DNA polymerases to add nucleotides to a
preexisting small piece of DNA called primer which is complementary to the beginning
of the template region to be amplified. In the case of the experimental technique here
presented, PCRs were performed but not only for the amplification of the strand of DNA.
Exploiting PCRs basic principle, another different purpose was sought: to first mutate and
then amplify a DNA sequence.
In order to explain the method in an precise way, the first round of mutagenesis will be
used as example to determine which reagents and components are needed in the process
and which outcomes are expected from each reaction. Nevertheless, to perform the fourth
round of mutagenesis, the same protocol was followed and the only change applied was
the pair of primers used to mutate the sequence.
As seen in Fig. 3.2, the first two steps applied in The Three PCRs Method for the first
round of mutagenesis consist of:
• PCR1: a PCR performed with a high fidelity DNA polymerase that elongated two
pair of primers (MR-mut1-r and DHOd) by using as template the huDHOase in
pOPIN-M. With this PCR1, a small piece of the whole huDHOase sequence is ex-
pected to be amplified, but with the singularity that this PCR1 product contains at
its 3’ end the particular mutations given by the primer MR-mut1-r that, despite con-
taining mutations in the middle of its sequence, annealed properly to the template.
• PCR2: a PCR performed with a high fidelity DNA polymerase that elongated a
different pair of primers (MR-mut1-d and DHOr3) by using as template the huD-
HOase in pOPIN-M. In this case, a bigger and different sequence corresponding
to the end of the huDHOase template is amplified with the mutations the primer
MR-mut1-d introduces when extension of its sequence happens.
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Fig. 3.2. Diagram representing the process behind the synthesis of both PCR1 and PCR2 products
from huDHOase in pOPIN-M (depicted in green). Arrows represent the primers that
direct the elongation and contain the mutations desired (red crosses) to make two
mutated DNA fragments different in size represented in yellow, PCR1 and PCR2.
The reaction mix of 100 µl prepared for PCR1 consisted of: 20 µM of primer DHOd
(Sigma), 20 µM of primer MR-mut1-r (Sigma), 10 mM deoxynucleotide triphosphate
(dNTPs; ThermoFisher), Buffer Phusion 5X (New England Biolabs), 2u Phusion poly-
merase (New England Biolabs) and 100 ng of pOPIN-M-huDHOase. In the case of PCR2,
the 100 µl reaction mix consisted of: 20 µM of primer DHOr3 (Sigma), 20 µM of primer
MR-mut1-d (Sigma), 10 mM dNTPs (ThermoFisher), Buffer Phusion 5X (New England
Biolabs), 2u Phusion polymerase (New England Biolabs) and 100 ng of pOPINM-M-
huDHOase.
For both PCR1 and PCR2, the conditions used in the thermal cycler24 (SimpliAmp
Thermal Cycler, ThermoFisher) were as presented in Fig. 3.3 and their reaction mix sep-
arated into two tubes of 50 µl to allow for a more uniform change of temperature in the
solutions.
Fig. 3.3. Thermal Cycler conditions used to obtain PCR1 and PCR2.
Once the 30 cycles of the PCR were finished, the two 100 µl reactions were loaded in
24laboratory instrument that expose a PCR reaction to different temperatures during programmed periods
of time and cycles inducing the reagents of the reaction to amplify the DNA
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a 1.2% agarose (CONDA) gel [27], stained with GelRed (Biotium) and observed under
UV light with a Slite 140S transilluminator (Pacific Image Electronics) for agarose gel
electrophoresis25. Subsequently, the bands corresponding to PCR1 and PCR2 that ran up
to the expected sizes, were cut and purified with a QUIAGEN Gel Extraction Kit.
The last step to complete the Three PCR Method presented in Fig. 3.4, is a final PCR
addressed as PCR3:
• PCR3: PCR performed with a high fidelity DNA polymerase using primers DHOd
and DHOr3 to elongate products PCR1 and PCR2 that now act as templates of
each other. These two fragments will anneal in the PCR reaction as they share a
complementary (and mutated) piece of sequence on their 3’ ends. When annealing
of both the products and the primers takes place, elongation with the DNA poly-
merase occurs and the final product addressed as PCR3 results in the complete and
non-fragmented huDHOase sequence mutated with the bases sought in the middle.
Fig. 3.4. Diagram showing how, from a pair of primers annealed at the ends of both PCR1 and
PCR2 products, the complete huDHOase sequence is synthesized with the mutations
sought (red crosses).
An important detail to take into account is that, as the PCR1 product is 2.5 shorter in
length than the product from PCR2, the reaction must contain double the amount of PCR1
product in comparison with the concentration of PCR2 product added. Therefore, the 100
µl reaction mix consisted of: 20µM of primer DHOd (Sigma), 20 µM of primer DHOr3
(Sigma), 200 ng PCR1 product, 100 ng PCR2 product, 10 mM dNTPs (ThermoFisher),
Buffer Phusion 5X (New England Biolabs), 2u Phusion polymerase (New England Bio-
labs) and 5% DMSO (ThermoFisher).
As the PCR3 requires only the use of primers DHOd and DHOr3, as seen in Fig. 3.5
the temperature of annealing in the Thermal Cycler was set to 60ºC as this primers present
the most efficient annealing at this temperature. However, as the same DNA polymerase
25technique used for the separation of DNA fragments according to their size by their differential migra-
tion in an agarose matrix
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was used, the denaturation and elongation temperatures were kept the same as the ones
used for PCR1 and PCR2. The last change implemented was the numbers of cycles (35)
in order to increase the amount of amplified product.
Fig. 3.5. Thermal Cycler conditions used to obtain PCR3.
Once the 35 cycles of the PCR were finished, the 100 µl reaction was loaded in a 0.8%
agarose (CONDA) gel and stained with GelRed (Biotium) [27]. To observe the stained
band under UV light, a Slite 140S transilluminator (Pacific Image Electronics) was used
and subsequently, the band that ran up to the expected size for PCR3, was cut and purified
with a QUIAGEN Gel Extraction Kit.
3.1.4. Temperature gradient tests
Each primer used in this project (DHOd, DHOr3, MR-mutX-d, MR-mutX-r) required for
a specific temperature of annealing to attach properly to the template and let the poly-
merase incorporate the nucleotides. However, this implies that, when several of them
are used in the same PCR reaction, a particular temperature that fits all the primers must
be chosen for setting the Thermal Cycler conditions. To check for the appropriate tem-
perature that provides with the maximum amplification, in both the Three PCRs Method
and the QuikChange Site-directed Mutagenesis, several 25 µl of volume control reactions
were performed with the primers needed in each round.
By employing a Thermal Cycler with Gradient option (MasterCycler, Eppendorf),
PCR reactions were prepared with the primers to be tested and the rest of the reagents
explained in section 3.1.3. Setting the instrument to give a different annealing temperat-
ure to each tube, the most suitable temperature was chosen by looking at the width and
intensity of the amplification bands of each well in an agarose gel.
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3.1.5. In-Fusion reaction
The resultant outcome from the Three PCRs Method (product PCR3) is a linear sequence
with blunt ends at the 5’ and 3’ terminals. To clone this fragment into bacteria, it must
be ligated to a linearized plasmid in order to get a circular plasmid that, among many
genes, has inserted the mutated huDHOase sequence coming from the PCR3. The tool
used to achieve that ligation was the In-Fusion HD cloning Kit (Clontech). In this kit, an
enzyme called In-Fusion is in charge of fusing both the PCR3-generated fragment and the
previously linearized vector, pOPIN-M. This enzyme recognized the flanking bases of the
PCR3 fragment, as they are complementary to the ends of the linearized pOPIN-M (these
bases were inserted by the primers DHOd and DHOr3 during the obtaining of PCR1 and
PCR2), and joined both into a circular plasmid-like structure.
To prepare the In-Fusion reaction (PCR3 insert + pOPIN-M vector + In-Fusion Buf-
fer 5x), Clontech’s In-Fusion Calculator tool was used to determine the amount of vector
and insert that was needed to obtain a high yield on the ligation. By inserting the size in
base pairs for both of them, the amounts in nanograms that should be added are retrieved
and for a 5 µl reaction, each reactant concentration was adjusted to match the recom-
mendations from the manufacturer. After mixing the vector and insert in the In-Fusion
Buffer 5x, the tube was kept at 50ºC for 15 minutes to let the enzyme perform its function.
As it will be explained in section 3.1.7, every time the In-Fusion reaction was done,
a parallel control reaction with the same reagents except for the insert, which was sub-
stituted by milliQ water, was prepared. This control reaction was plated to make sure
that the colonies that appeared in the In-Fusion petri dish did not emerge as a result of
supercoiled plasmids 26 that did not insert the genetic material aimed during the In-Fusion
reaction but, because they religated inside bacteria, they became resistant to the antibiotic
of the plate and let colonies grow.
3.1.6. QuikChange Site-directed Mutagenesis
After the first round of mutagenesis in which the Three PCRs Method was used, the
second and third rounds were done using a new strategy (Fig. 3.6) in which only one PCR
is performed and an additional digestion step is needed. Generally, this method consist
on:
1. Creating a so-called parental plasmid by ligating the template that will be used for
mutation with a new plasmid, pCRTM-Blunt.
2. Transformation of bacteria for the obtaining of methylated parental plasmids.
26twisted and tangled linear plasmids
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3. Perform a PCR in which, after denaturation of the parental circular template, exten-
sion of the primers allow the synthesis of mutated nicked DNA.
4. Digestion of the remaining methylated parental non-mutated plasmid with DpnI so
only mutated DNA is left.
Fig. 3.6. QuikChange Site-directed Mutagenesis approach scheme.
Firstly, the PCR3 product coming from the first round, that now functions as template
for the next mutagenesis, was ligated to the plasmid provided by the Kit, pCRTM-Blunt
(Fig. 3.7). To induce the ligation, a molar ratio of 1:3 vector pCRTM-Blunt to insert
(PCR3 fragment coming from round 1) was prepared, with the addition of the Ligation
Buffer 10X and 0.5 units of T4 DNA ligase per µl of the final volume of the reaction.
To avoid the self ligation of the plasmid without the insert, the pCRTM-Blunt was pur-
chased already dephosphorilated. This dephosphorilation is needed as the T4 Ligase can
only join the 3’ hydroxyl group of one end with the 5’ phosphate group of the other end.
Therefore, for ligation to occur, at least one of the DNA ends (insert or vector) must con-
tain a 5’ phosphate group, in the case of this project the insert.
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Fig. 3.7. Map of circular plasmid pCRTM-Blunt.
After incubation for one hour at 16ºC, 4% of the ligation reaction was used for the
transformation of TOP10 cells. In this step, methylation of the plasmid by bacteria is a
key step as the parental non mutated plasmid must be eliminated at the end of the pro-
cedure. Moreover, the peculiarity about pCRTM-Blunt is the presence of a lethal gene,
ccdB, used to avoid false positives. This gene, inducing the death of the bacteria that has
incorporated the plasmid, gets inactivated only when a DNA fragment is inserted in the
middle of its sequence, preventing its expression. Therefore, colonies were able to grow
in the plate due to the interruption of this gene by the PCR3 insert, a confirmation that all
of them contained the proper ligation sought.
With the ligated construct ready and verified by Sanger sequencing, a single PCR
with the corresponding pair of mutagenic primers and a proofreading DNA polymerase
was done. In final volume of 20 µl the reaction consisted of: pCRTM-Blunt ligated with
PCR3, 2.5 µM of primer MR-mut2-d (Sigma), 2.5 µM of primer MR-mut2-r (Sigma), 10
mM dNTPs (ThermoFisher) , Buffer Exp.Long 10X (Sigma), 3.5 u Expand Long Sys-
tem Polymerase (Sigma) and 2% DMSO (ThermoFisher). The conditions for the thermal
cycler were adapted to the new polymerase and for the annealing temperature, as the
QuikChange method was used for the second and third rounds, the PCR was set at 68ºC
in the annealing step as both pair of primers showed the greatest amplification with this
temperature.
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To eliminate only the methylated remnants of parental non-mutated plasmid in the re-
action, digestion with 10 u of methylation-dependent endonuclease DpnI was done for an
hour at 37ºC. After the treatment with DpnI, transformation of TOP10 was followed and
the colonies obtained were inoculated to perform Minipreps27 (GeneJET Plasmid Mini-
prep Kit, Thermo Fisher).
When the plasmid was isolated from bacteria, Sanger sequencing was used to verify
that the sequence was properly mutated. The construct (pCRTM-Blunt with huDHOase
mutated up to round 2) was then used as template (no need for ligation step) to directly
perform the site directed mutagenesis following the same procedure but this time using
the primers corresponding to the third round (MR-mut3-d, MR-mut3-r).
3.1.7. Transformation of cells
In order to obtain a greater amount of methylated plasmids after using the In-Fusion tech-
nology or during the QuikChange Site-directed Mutagenesis, a transformation protocol
was performed. In this protocol, the ability of E.coli bacteria to incorporate, methyl-
ate and replicate foreign external DNA material, was exploited to obtain exclusively the
methylated plasmids that contained the mutated inserts desired for each round.
In this transformation procedure, aliquots of the TOP10 competent cell strain (Thermo
Fisher) were gently mixed with 5-10% of the In-Fusion or QuikChange reactions and left
on ice for 30 minutes in order for the bacterial outer membrane to stabilize. After that,
the tubes were incubated in a water bath at 42ºC for 45 seconds in order for the heat to
change the fluidity of the cell membrane and let the foreign genetic material to enter the
cell. Immediately after the heat shock, the bacteria were put on ice for 3 minutes and then
recovered with 300 µl of LB media culture for 1 hour at 37ºC in a shaker at 400 rpm.
To plate the bacteria, LB+Agar petri dishes were prepared with the addition of an an-
tibiotic. In the case of the In-Fusion technology, every time transformation of cells was
done after the procedure, Ampicillin 1000X was used. For the QuikChange reaction the
antibiotic chosen was Kanamycin 1000X. The reason for the use of different antibiotics
for each technology comes from the fact that the plasmid pOPIN-M contains in its se-
quence a gene that confers resistance to ampillicin, while pCRTM-Blunt has a kanamycin
one. In this way, only the bacteria that incorporates the plasmid into their cytoplasm
acquires resistance to the antibiotic and is able to produce colonies in the antibiotic-
containing agar plate. This is a common protocol to make sure that the colonies that
appear in the petri dish have incorporated the genetic material aimed and no false posit-
27small scale procedure to isolate plasmid from bacteria
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ives are used in further steps.
However, as supercoiled vectors can also knit their ends inside bacteria and express
the antibiotic resistance gene, a control reaction against false positives, without insert and
only vector, was always performed in the In-Fusion technology and plated along with the
other In-Fusion reactions. In this plate, if no colonies were obtained, it implied that the
vector used did not present supercoiling and the colonies that appeared in the other petri
dishes plated with the In-Fusion reaction were all positive colonies with the insert+vector
construction.
3.1.8. NaeI digestion test before sequencing
Before sending any plasmid for Sanger sequencing, Serial Cloner’s Virtual Cutter tool
(Serial Basics) was used first to find a restriction enzyme that could cut the plasmids,
coming from each round of mutagenesis, in different sizes and fragments giving char-
acteristic patterns. NaeI was the enzyme meeting the aforementioned requirement and
digestion reactions were prepared at the end of each round. The concept behind the use of
this enzyme is its ability as endonuclease to cleave DNA at distinct recognition sites. In
this way, if the mutations performed at each round added or deleted any recognition site
for NaeI in the sequence, then the enzyme would cut the DNA into more/less fragments
with different sizes. As a consequence, by loading the digestion reaction (the plasmid cut
by NaeI) into an agarose gel and comparing the number and size of the bands of the gel
with the theoretical virtual cut, the mutations could be roughly confirmed before sequen-
cing and no false positive would be sent.
Therefore, to exploit NaeI endonuclease function in the last three rounds of mutagen-
esis, digestion for one hour at 37ºC was done on reactions composed by 0.3 u/µl NaeI,
CutSmart Buffer 10X (New England Biolabs) and 0.05 µg/µl plasmid (final product of
each round of mutagenesis).
3.1.9. Preparation and analysis of sequencing results
To obtain confirmation on the step-by-step mutations, the plasmids of interest were pre-
pared in a 200 ng/µl concentration and added to a pair of forward and reverse primers at
10 ng/µl. In this way, by elongation of both primers and the analysis by Sanger sequen-
cing28 on the resultant region of DNA, chromatograms were retrieved and evaluated to
verify the mutations.
28technique used to determine the order of nucleotides of a DNA strand
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For the visualization and verification of the Sanger sequencing results provided by the
company Stab Vida, the chromatograms files were read with the 4peaks (Nucleobytes)
software. Furthermore, to analytically compare amino acids and bases, and see if the
sequence to be reached after each round was obtained, four virtual plasmid constructs
with the huDHOase mutated according to each round were built with Serial Cloner (Serial
Basics). These virtual mutated constructs were aligned to the Sanger sequencing results
so the parity of bases and the presence of the mutations could be visually inspected and
ease the confirmation of success.
3.2. Plasmid expression, protein production
To produce the protein on a large-scale, the final mutated construct addressed as pOPIN-
M-huDHOase-ELF (ELF for: E.coli loop flexible) was expressed in a suspension of
HEK293S-GnTI- cells (mammalian cells that perform suitable post-translational modi-
fications) in Freestyle medium (Gibco) with 1% fetal bovine serum. For the transfection
of these cells, the huDHOase-ELF plasmid was mixed with polyethylenimine (PEI: 25
kDa branched, Sigma), a polymer that binds to the DNA creating polyplexes and allows
its delivery through the lipid bilayer, releasing it to the cytoplasm for its expression [28].
For the complexation, a 1:3 ratio mixture of DNA (1 µg/ml) and PEI was prepared by
first diluting huDHOase-ELF to 20 µg/ml and PEI to 60 µg/ml in UltraDOMA medium
(Lonza). Both dilutions were incubated for 5 minutes at room temperature and, after care-
fully mixing both solutions, another incubation step of 15 minutes was followed. The mix
was then added to the cell culture and kept in an orbital stirrer at 125 rpm at 37ºC and 5%
CO2 for three days.
To test the transfection efficiency of the PEI used, plasmid pCMV-GFP (Addgene)
containing the sequence for GPF29 (Green Flourescent Protein) was complexated with
PEI following the same protocol and transfected to a 25 ml sample of the cells. After
three days, by using a hemocytometer and fluorescence microscopy on the sample (Leica
Microscope DMLB Fluorescence and Phase Contrast), the amount of cells exhibiting
green fluorescence were counted as well as the total number of cells on the four cham-
bers of the hemocytometer. As the green fluorescence denotes the internalization of the
polyplexes by the cells, the final efficiency of transfection was calculated as:
PEI Transfection Efficiency =
Number of cells that express GFP
Total number of cells
× 100 (3.1)
Afterwards, the cells transfected with pOPIN-M-huDHOase-ELF were harvested by
centrifugation at 2500 rpm for 20 min and kept at -80ºC until the purification process.
29protein isolated from yellyfish that emits green fluorescence when exposed to UV light
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3.3. Protein purification
To obtain the protein of interest huDHOase-ELF, two types of chromatography techniques
were used (Fig. 3.9). Chromatography is used to separate components in a mixture by
passing this mixture, contained in a mobile phase, through a stationary phase that inter-
acts with the samples as they move past it. Depending on these types of interactions, the
mobile phase can be partitioned in its elution and the samples of interest can be collected.
For the monitoring of the presence, purity, size and concentration of the protein, SDS-
PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) [29] and Bradford
Assay [30] were used after each step of the purification.
3.3.1. Immobilized Metal Affinity Chromatography
The cell pellet was first resuspended in buffer NiA (20mM Tris pH 8, 500 mM NaCl,
5% Glycerol, 10 mM Imidazole, 2mM β-mercaptoethanol, 2mM phenylmethanesulfonyl-
fluoride) and, by using a dounce homogenizer30, the cells were subjected to shear in order
to disrupt their membrane. To properly lysate the cells, the sample was sonicated by ex-
posing it to pulses of 20 kHz for 15 seconds 5 times (all pulses followed by a resting
period of 15 seconds) and kept on ice during all the process due to the possible overheat-
ing from the sonicator. Then, the lysate was centrifuged at 40,000 rpm for one hour at
4ºC and the supernatant obtained was filtered with a 0.45 µm membrane filter to avoid
straining the Nickel Cartridge (ABT) [15].
As mentioned in section 3.1.1, the pOPIN-M-huDHOase construct used in this project
was designed with several motifs in order to perform the transformation and purification
steps. When the cell expressed the plasmid and produced the protein, as the plasmid had
the 6xHis tag, MBP and PS site sequence immediately upwards to the huDHOase-ELF
sequence, it attached these motifs to the N-terminal end of the huDHOase-ELF (Fig. 3.8)
giving a recombinant protein with key elements to use for its purification.
Fig. 3.8. Graphical scheme of the sequence aimed to be expressed in HEK293S-GnTI-cells.
Before the sequence of huDHOase-ELF there is a tag consisting of six histidines,
the sequence coding for the MBP and a site for cleavage by the PreScission protease.
30device used to aid the complete lysis of cells by tissue grinding
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To first separate the huDHOase-ELF from the rest of the components of the lysate,
immobilized metal affinity chromatography (IMAC) was used with a 5 ml Nickel Cart-
ridge (Number 3 in Fig. 3.9) from ABT. Prior equilibration of the Nickel Cartridge with
10 volumes of buffer NiA, the lysate was loaded into the cartridge and, due to the high
affinity of the 6xHis tag attached to the huDHOase-ELF to the nickel beads of the resin,
the whole protein remained embedded in the cartridge adhered to the nickel.
Fig. 3.9. FPLC (a.) and HPLC (b.) equipment used for the purification of huDHOase-ELF and
their shared diagram (c.). Key parts of the HPLC system while doing IMAC are
enumenrated. FPLC share the same components but with a vertical column instead of a
cartridge.
The Nickel Cartridge was then connected to a high performance liquid chromato-
graphy system (ÄKTAprime plus HPLC, GE healthcare) and by washing it with 10%
buffer NiB (20mM Tris pH 8, 500 mM NaCl, 5% Glycerol, 250 mM Imidazole, 2mM β-
mercaptoethanol) the possible contaminants with low affinity to the nickel were removed.
To elute the protein, 100% of buffer NiB (250 mM Imidazole) was injected into the cart-
ridge so the high concentration of imidazole could compete against the protein for the
nickel of the cartridge and detach it [15].
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3.3.2. Dialysis and Digestion
To continue with the purification procedure, the concentration of imidazole in which the
protein was eluted (250 mM) had to be reduced. To achieve this decrease of concentration,
the protein was kept in a dialysis membrane (Sigma) against a dialysis buffer (20 mM Tris
pH 8, 500 mM NaCl, 5% Glycerol, 30 mM Imidazole, 2mM β-mercaptoethanol) at 4ºC
overnight.
To digest the protein and remove the 6xHis tag and the MBP, leaving only the huDHOase-
ELF construct, PreScission protease that cleaves at the PS site (GE Healthcare) was added
to the buffer NiA in a 1/20th relation of the protein molecular weight and left overnight
while dialysis took place. To extract the huDHOase-ELF protein, the nickel cartridge was
connected again to the HPLC and, by injection of the digestion mixture and the dialysis
buffer with 30 mM Imidazole, the huDHOase-ELF alone was recovered in the elution
while the 6xHis tag and the MBP remained attached to the nickel beads of the cartridge’s
resin. To detach the 6xHis Tag + MBP from the resin, buffer NiB with 250 mM Imidazole
was then injected into the cartridge.
3.3.3. Gel Filtration: Size Exclusion Chromatography
After concentration of the protein by centrifugation with the Amicon Ultra filters system
(Sigma; 10 kDa cut off membrane), a gel filtration step was performed to purify the pro-
tein by size exclusion chromatography (SEC). For this protein, a Superdex 200 10/300
column was used (GE Healthcare) on a Fast Performance Liquid Chromatography sys-
tem (ÄKTAFPLC, GE healthcare). The buffer prepared for the elution of the protein and
the prior equilibration of the column consisted of 20mM Tris pH 8, 150 mM NaCl, 20
ZnSO4 and 0.2 mM TCEP. The protein was loaded into the column and several fractions
of volume (from 1 to 20) were retrieved. To determine in which fraction the protein of
interest eluted, the Superdex 200 10/30 column calibration chromatogram provided by
the manufacturer was used to extrapolate the peaks, corresponding to known molecular
sizes, with the results obtained for the huDHOase-ELF. In this calibration test, several
proteins with known molecular weight were passed through the column and eluted at dif-
ferent volumes depending on their size inducing different peaks of absorbance (measured
at 280 nm). Therefore, with this test in consideration, the fractions of volume with the
size corresponding to the elution of huDHOase-ELF were chosen.
To complete the purification procedure, the sample was concentrated using an Ami-
con Ultra filter system (Sigma; 5 kDa cut off membrane) and the final concentration of the
protein was measured by Bradford Assay at 595 nm on a spectrophotometer (BioSpectro-
meter, Eppendorf) [30].
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3.4. Activity assays on wt-huDHOase and huDHOase-ELF
To test the enzymatic activity of the huDHOase-ELF, activity assays of this protein and
the wild type huDHOase were performed in parallel. Both proteins activities were assayed
following the same procedure, the continuous measurement of absorbance from a spec-
trophotometer (BioSpectrometer, Eppendorf) at 230 nanometers, as at this wavelength the
spectrophotometer can measure the concentration of the product dehydroorotate (DHO)
present in the reaction [31].
For obtaining a reliable result, both directions of the enzymatic reaction: produc-
tion of product DHO and production of substrate carbamoyl phosphate (CA-asp) (Fig
3.10), were reproduced in four essays that were performed in parallel on the chimeric
huDHOase-ELF and wild-type huDHOase. In this way, the change on absorbance meas-
ured by the spectrophotometer in real time determined the ability of each enzyme to pro-
duce the product DHO from the substrate CA-asp (indicated by the increase of the absorb-
ance measurements) or the use of DHO to produce the substrate CA-asp (by observing the
decrease of the absorbance measurements). These four assays were conducted as follows:
I. Addition of CA-asp to wt-DHOase: retrieval of product production rate for the wild
type huDHOase.
II. Addition of CA-asp to huDHOase-ELF: retrieval of product production rate for the
chimeric huDHOase-ELF.
III. Addition of DHO to wt-huDHOase: retrieval of substrate production rate for the
wild type huDHOase.
IV. Addition of DHO to huDHOase-ELF: retrieval of substrate production rate for the
chimeric huDHOase-ELF.
Protein
to
be tested
Direction
of
the reaction
Compound
added
to the reaction
Molecule
produced
in the reaction
Times the
experiment
was repeated
I wt-DHOase forward CA-asp DHO 3
II huDHOase-ELF forward CA-asp DHO 3
III wt-DHOase reverse DHO CA-asp 3
IV huDHOase-ELF reverse DHO CA-asp 3
TABLE 3.3. SUMMARY OF THE ACTIVITY EXPERIMENTS
PERFORMED ON WT-HUDHOASE AND HUDHOASE-ELF
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Fig. 3.10. Reversible cyclization reaction of CA-asp catalyzed by huDHOase and reproduced in
the activity assays for wt-huDHOase and huDHOase-ELF.
To test the product production rate of both proteins, 10 µM wt-huDHOase was added
to Activity Buffer A (50 mM NaPi pH 5.0, 150 mM NaCl, 0.1 mg/ml BSA and 20 µl
ZnSO4) in a final volume of 95 µl and 10 µM huDHOase-ELF was added in a separate
tube to buffer A in a final volume of 95 µl. By filling two cuvettes with each reaction,
the test started by taking 4-5 measures of the absorbance of the proteins alone without
addition of the substrate. Once a stable measurement was obtained, 100 mM CA-asp was
added to each cuvette and mixed fast by pipetting up and down for a few seconds while
the spectrophotometer took an absorbance measure every 5 seconds for 5 minutes. The
experiment was repeated three times for each protein and the data retrieved from the spec-
trophotometer’s files were analyzed with GraphPad Prism.
For the evaluation on the substrate production rate favored by pH 8.5, 10 µM wt-
huDHOase was added to Activity Buffer B (50 mM NaPi pH 8.5, 150 mM NaCl, 0.1
mg/ml BSA and 20 µl ZnSO4) in a final volume of 95 µl while 10 µM huDHOase-ELF
was added in a separate tube to buffer B in a final volume of 95 µl. Two cuvettes were
filled with each reaction and, again, the test began with 4-5 measures of the protein ab-
sorbance alone. Once the measurements were stable, 10 mM DHO was added to each
cuvette and rapidly mixed with a pipette for a short time while the spectrophotometer
took measures of absorbance every 5 seconds for 5 minutes. As before, the experiment
was repeated three times for each protein and the data retrieved from the spectrophoto-
meter’s files was analyzed with GraphPad Prism.
For the analysis of the data and the obtaining of the catalytic constant (kcat) in each
assay, the first few measurements (taken during the first seconds) were discarded as they
were obtained while the mixing and handling of the device were performed. Therefore, to
avoid this source of experimental error, all the outliers in the absorbance retrieved during
those seconds were excluded.
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To determine the activity of both proteins and compare them, the catalytic constant
kcat was computed. This constant kcat, also called the turnover number, is a first order
rate constant with reciprocal units of time that describes the limiting catalytic rate of an
enzyme at saturation. Therefore, this kcat represents the number of substrate molecules
[S] transformed into product [P] in a given unit of time on a single enzyme [E] when this
molecule is saturated with substrate [1].
E + S −⇀↽−
ES
E + P
As the concentration of substrate added was three orders of magnitude higher than
the concentration of enzyme, a steady state can be assumed. In this state, all the active
sites of the enzyme are taking part in the [ES] complex and both rates of formation and
breakdown of the [ES] complex are in equilibrium. Therefore, the kcat can provide with
the efficiency of the protein’s catalytic behaviour in saturation.
kcat =
Vmax
[E]t
(3.2)
kcat =
moles of DHO produced
min · concentration of protein added (3.3)
A first plot was done to represent the absorbance measurements (in OD) at each time
point in order to obtain the slopes (speed of the reaction) of each assay in OD/min. Then,
to transform the measurements of absorbance into the concentration of DHO produced as
a function of time (µM/min), the Beer-Lambert law was used [32]:
A = ε · b ·C (3.4)
Where A is the slope of the absorbance vs. time plot of each assay (OD/min), ε is the
extinction coefficient31 of DHO at 230 nm (1.17 mM-1 cm-1 [8]), b is the path length of the
31a measure of how strongly a substance absorbs light at a particular wavelength
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light through the cuvette (1 cm) and C is the concentration of DHO per minute (M/min).
Finally, to obtain the kcat of the wild type huDHOase and huDHOase-ELF in the two
directions of the reaction, the concentration of DHO produced given by the Beer-Lambert
law was divided by the concentration of protein added in the assay (0.5 µM) and, as
each experiment was performed three times, the final four kcat were given as an average
between the three assays with their respective standard deviation.
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4. RESULTS
4.1. Cloning of huDHOase
4.1.1. Obtaining of PCR1 PCR2 and PCR3 fragments
For the first and fourth rounds of mutagenesis in which The Three PCR’s Method was
used, agarose gel electrophoresis gave a preliminary confirmation of the successful amp-
lification of the DNA fragments by PCR. However, despite these bands being helpful to
characterize the successful PCRs, they did not give any information about the presence of
the aimed mutations. Further confirmation of the lengths and mutations of the fragments
were obtained by chromatogram analysis after sequencing.
On the one hand, the 1.2% agarose gel in Fig. 4.1a shows how, for PCR1, a band
appeared between the 250 and 500 bp size markers from the standard. This band corres-
ponded to the 333 nucleotides fragment of huDHOase aimed to be mutated with the first
three amino acids from E.coli flexible loop, plus 20 additional bases. These bases came
from the DHOd flanking nucleotides that do not match the huDHOase sequence and were
added to the sequence by elongation of the primer.
(a) Agarose gel loaded with the
resultant PCR1 and PCR2
amplified by PCR for the 1st
mutagenesis.
(b) Agarose gel loaded with the
resultant PCR3 amplified by
PCR for the 1st mutagenesis.
Fig. 4.1. Agarose gels providing with prior evidence on the obtaining of huDHOase fragments
mutated according to the first round of mutagenesis.
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Besides the PCR1 loaded well, another band corresponding to the loaded PCR2 reac-
tion showed next to it. This band, between the 750 bp and 1000 bp size markers, coincided
with the last 879 bases from the huDHOase also targeted to be mutated with the first three
amino acids from E.coli flexible loop. Similarly to PCR1, to the previous 879 bases, 18
additional flanking nucleotides coming from the DHOr3 made a total of 897 nucleotides
for the PCR2 construct.
On the other hand, as seen in Fig. 4.1b, the first time the PCR3 was performed, three
distinct bands appeared in the gel. The first band, thicker and between the 1000 bp and
1500 bp size standards, coincided with the expected PCR3 fragment comprising 1211
nucleotides (the entire huDHOase sequence mutated with the first three amino acids from
E.coli flexible loop plus the flanking bases from both DHOd and DHOr3 primers). Un-
expectedly, below this band, two other blurry ones appeared. Further discussion on the
presence of these two products can be found in Chapter 5.
Similar gels to Fig. 4.1 were obtained for the final fourth round of mutagenesis in
which the fragments appeared between the same size markers although the sizes in this
case were 383 bp for the PCR1, 876 bases for PCR2 and finally the whole mutated PCR3
fragment with the flanking bases from primers DHOd and DHOr3: 1217 bases. In the
case of this fourth round of mutagenesis, no additional unexpected bands were obtained
in the well corresponding to PCR3, but in PCR1 and PCR2. As before, refer to Chapter 5
for the discussion on this blurry bands appearing below the cuts.
In Fig. 4.2 a look on the resultant appearance of the excised gels from the 4th round is
included. Special attention must be paid to the thin bands left on the wells of Fig. 4.2a.
(a) Agarose gel resultant from cutting
both PCR1 and PCR2 bands of 4th
mutagenesis.
(b) Agarose gel
resultant from
cutting PCR3
band of 4th
mutagenesis.
Fig. 4.2. Excised agarose gels showing the successful extraction of all three PCR products after
the 4th round of mutagenesis for subsequent DNA purification.
39
4.1.2. Temperature gradient tests
The gradient of annealing temperatures done to the primers from Table 3.2 revealed dif-
ferent sets of temperatures as the most amplifying–effective. On one side, all MR-mutX-r
(the reverse primers for all rounds of mutagenesis) showed thicker and crisp bands ex-
clusively from 52ºC to 55ºC reactions while for MR-mutX-d (the direct primers for all
rounds of mutagenesis) irregular patterns were obtained in the gels, being 62ºC and 68ºC
the only noteworthy temperatures showing a high amplification yield. An example on the
appearance of the bands can be seen in Fig. 4.3a.
Regarding the DHOd and DHOr3 primers, in Fig. 4.3b, robust PCR3 bands were
obtained only when the temperature exceeded 60ºC. Red arrows point towards unwanted
PCR products, significantly of lower intensity at 65ºC of annealing.
(a) PCR1 and PCR2 done in a gradient of ten temperatures to test the
amplification yield of MR-mut4-r (left gel) and MR-mut4-d (right gel).
(b) PCR3 done in a gradient of three
temperatures with DHOd/DHOr3.
Fig. 4.3. Gradient tests done for the Three PCRs Method in order to choose the appropriate
annealing temperatures of the primers.
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4.1.3. Ligation of huDHOase with pCRTM-Blunt
After performing the ligation of pCRTM-Blunt with the huDHOase sequence containing
the mutations from the first cloning round, the chromatogram (Fig. 4.4a) retrieved from
Stab Vida confirmed two facts: the mutation of the first three amino acids of the huD-
HOase flexible loop into the first three amino acids of the ecDHOase flexible loop, P A
N: L1559P, N1560A, E1561N; the flanking bases before and after the huDHOase fragment
corresponded to the pCRTM-Blunt. With both mutation and ligation confirmed, the used
of the QuikChange Site-directed Mutagenesis approach was approved to be continued.
(a) Chromatogram showing evidence of the first
three amino acids mutated: P A N
(b) Alignment of the theoretical construction made in Serial Cloner (Seq_1) with
the sequencing file (Seq_2) from Stab Vida. Bases that comprise the first round
of mutagenesis are highlighted in green.
Fig. 4.4. Results obtained by Sanger sequencing in which both the ligation of huDHOase with
pCRTM-Blunt and the first round of mutagenesis are verified.
4.1.4. Digestion with NaeI
The use of NaeI to digest the plasmids before sending them for Sanger sequencing, res-
ulted in gels like the ones showed in Fig. 4.5 and Fig.4.6. As seen in Fig.4.5, the loaded
pCRTM-Blunt plasmid mutated up to the second round evidenced the accuracy of Serial
Cloner’s Virtual Cutter as the four characteristic bands given by the software were ex-
perimentally obtained. The next 8 wells, loaded with 8 plasmids samples coming from
different colonies after the third round of mutagenesis, all showed an identical pattern that
matched the theoretical cut from the construction made with Serial Cloner. Therefore, as
the digestion showed in an indirect way that the huDHOase of the plasmids was mutated
as intended, all eight plasmids were considered suitable for verification though sequen-
cing.
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Fig. 4.5. Agarose gel loaded with NaeI-digested plasmids from the 2nd and 3rd rounds of
mutagenesis next to a graphic report from Serial Cloner’s Virtual Cutter. As the bands of
the gel followed the pattern dictated by the Virtual Cutter, the mutations planned on both
plasmids were considered accomplished.
Similarly, in Fig. 4.6, the bands of the gel showed how the enzyme digested dif-
ferently the plasmid containing the huDHOase sequence mutated up to the third round
(previously verified through sequencing) and the plasmid isolated from a colony from the
fourth round. And, at the same time, they matched with the theoretical patterns expected
from the virtual cut done. Thus, the three bands were considered proper evidence of the
presence of the mutations and the cloning procedure was foreseen as terminated pending
for the final corroboration from Sanger sequencing.
Fig. 4.6. Agarose gel loaded with NaeI-digested plasmids from the 3rd and 4th rounds of
mutagenesis next to a graphic report from Serial Cloner’s Virtual Cutter. As both the
experimental and theoretically expected bands from Serial Cloner were obtained in an
exact arrangement, the mutation was considered successful.
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4.1.5. Sequencing results of the huDHOase-ELF
After each round was completed by the Three PCRs Method or the QuikChange Site-
directed Mutagenesis approach, the analysis of the chromatograms and the resultant se-
quencing files determined the progressive success on mutating huDHOase flexible loop
amino acids with the corresponding amino acids from ecDHOase flexible loop:
Human DHOase flexible loop L N E - T F S E L - R L D
E.coli DHOase flexible loop P A N A T T N S S H G V T
As shown in Fig. 4.7, the chromatogram ABI file retrieved shows: the insertion of
one alanine, N1561_T1562insA, and the mutation of a phenylalanine into a threonine,
F1564T. The bases comprising both the insertion and the substitution corresponded to the
bases of the designed primers and thus, the ones aimed.
(a) Chromatogram confirming the insertion of an
Alanine and the substitution of huDHOase F
into ecDHOase T
(b) Alignment of the theoretical construction made in Serial Cloner (Seq_1) with
the sequencing file (Seq_2) from Stab Vida. Bases that comprise the 2nd round
of mutagenesis are highlighted in light green while past mutations are marked in
dark green.
Fig. 4.7. Results obtained by Sanger sequencing of the pCRTM-Blunt vector ligated with
huDHOase in which confirmation of the insertion and mutation aimed for in the 2nd
round of mutagenesis was obtained.
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In Fig. 4.8 is presented the reading of the third chromatogram on 4peaks and the align-
ment on Serial Cloner with the theoretically expected construct for the third round. Both
show three substitutions in the huDHOase: S1565N, E1566S and L1567S (Fig. 4.8a) im-
mediately after the rest of changed bases from the past 1st and 2nd rounds that remained
unaltered (Fig. 4.8b).
(a) Chromatogram verifying the mutation of
huDHOase S E L to ecDHOase N S S
(b) Alignment of the theoretical construction made in Serial Cloner for the 3rd
round (Seq_1) with the sequencing file (Seq_2) from Stab Vida. Target bases
that comprised the 3rd round of mutagenesis are highlighted in light green while
past mutations and insertions are marked in dark green.
Fig. 4.8. Results obtained by Sanger sequencing of the pCRTM-Blunt vector ligated with
huDHOase in which confirmation of the mutations aimed in the 3rd round of
mutagenesis was obtained.
In the case of the fourth round, as can be seen in Fig. 4.9b: (1) three bases coding for
histidine were inserted (S1567_G1568insH) between the past mutated Serine and a Gly-
cine; (2) the last amino acids of the huDHOase flexible loop R L D were substituted into
G V T (R1569G, L1570V, D1571T); (3) an unexpected and unwanted base substitution
appeared, g.4695C>T, but the resulting codon32 translates into the same amino acid, an
asparagine on position 1565.
32sequence of three adjacent DNA bases that code for an amino acid when translation into protein occurs,
one of the rules that define the genetic code
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(a) Chromatogram showing the insertion of
three bases coding for histidine and the
mutations of the huDHOase sequence: R
L D into the ecDHOase sequence: G V T
(b) Alignment of the theoretical construction made in Serial Cloner for the 4th
round (Seq_1) with the sequencing file provided by Stab Vida (Seq_2). Bases
inserted and mutated in the 4th round are highlighted in light green while past
mutations and insertions are marked in dark green. The unwanted base
substitution is circled in orange.
Fig. 4.9. Results obtained by Sanger sequencing of the pOPIN-M vector ligated with huDHOase
in which confirmation of the insertion and mutations aimed in the 4th round of
mutagenesis was obtained.
4.2. Plasmid expression, protein production
After three days, 2.6 million of cells were obtained for the culture in which polyplexes of
huDHOase-ELF + PEI were transfected. Regarding the 25 ml control culture transfected
with the GFP contaning plasmid (pCMV-GFP), 21% efficiency was observed by fluor-
escence microscopy. An image of the cells while being counted on a hemocytometer is
shown on Fig. 4.10a while the production of the GFP protein and its expression of green
fluorescence can be seen on Fig. 4.10b.
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(a) HEK293S-GnTI- under the light microscope after being
transfected with plasmid pCMV-GFP.
(b) HEK293S-GnTI- under fluorescent microscopy after being
transfected with GFP containing plasmid pCMV-GFP.
Fig. 4.10. Analysis on HEK293S-GnTI- transfection efficiency by fluorescence microscopy.
46
4.3. Purification of huDHOase-ELF
4.3.1. Elution of the histidine tagged huDHOase-ELF bound to MBP after IMAC
As seen on Fig. 4.11, the chromatogram obtained from the HPLC system shows, as differ-
ent peaks of conductivity, both the discard of contaminants and the elution of the histidine
tagged huDHOase-ELF, still attached to MBP, in different fractions when IMAC was per-
formed.
After the wash with 10% NiB, a first conductivity peak of approx. 280 mAU appeared
10 minutes into the experiment. The eluted elements, taken since the growth of the peak
to its decline, were pooled in fractions 1, 2 and 3 and considered as contaminants. The
third 100 mAU peak, retrieved 40 minutes into the procedure and obtained after the in-
jection of 100% NiB to the cartridge, corresponds to the elution of the huDHOase-ELF
(along with other contaminants) which were collected from fraction 4 to 6.
Fig. 4.11. Graph retrieved from the HPLC system during IMAC. Contaminants correspond to
fractions 1 to 3 where a 280 mAU peak is observed. The 100 mAU of conductivity
peak corresponds to the elution of the protein of interest along with other contaminants
in fractions 4, 5 and 6.
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Fig. 4.12. SDS-PAGE gel loaded with a molecular size marker (st), the supernatant taken after
centrifugation of the cells, a sample of the pellet, the flow through after loading the
cartridge with the lysate, a contaminant sample from fraction 2 and the elution of the
protein from fraction 5.
Fig. 4.12 shows the SDS-PAGE gel prepared after the obtaining of the previous res-
ults. The elution well, corresponding to a sample coming from fraction 5, showed the
6xHis Tag + MBP + huDHOase-ELF between the 70 and 100 kDa size marks, along with
many contaminants of different size and abundance.
Up to this point, by measuring with Bradford assay [30], the concentration of the pro-
tein construct that eluted in 13 ml from fractions 4-6 gave 0.3 mg/ml.
4.3.2. Detachment of the 6xHis Tag and MBP through digestion
When the digested and dialyzed protein sample was loaded again into the cartridge, the
connected HPLC system returned the graphical tracking shown on Fig. 4.13. By injec-
tion of the dialysis buffer, the elutions corresponding to the first conductivity increment,
close to 40 mAU, were returned in 12 fractions among which the huDHOase-ELF was
retrieved. When 100% NiB was passed through the column, a second conductivity peak,
almost at 50 mAU, represented the pool of the 6xHis Tag and MBP on fractions from 13
to 19.
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Fig. 4.13. Chromatogram retrieved from the HPLC system showing the elution of the untagged
protein from fractions 1 to 12 in the 40 mAU peak, and the pool of the 6xHis Tag and
MBP on fractions from 13 to 19 almost at 50 mAU.
By looking at the SDS-PAGE gel on Fig. 4.14, the sample of huDHOase-ELF + 6xHis
Tag + MBP before digestion served as control, as again migrated between the 70 and 100
kDa markers of size. On its third well, a digested sample before its injection to the cart-
ridge for separation was loaded. In this case, three bands very close to each other showed
on the gel indicating the decoupling aimed. Fractions 2, 7, 9 and 11 ran above the 40 kDa
marker showing, unexpectedly, two bands. The bands which migrated from wells 13, 14,
15 and 16 confirmed the elution of the 6xHis Tag + MBP (approx. 40 kDa) and their
disassociation from the huDHOase-ELF.
After checking the SDS-PAGE gel, concentration by centrifugation was followed and
the 6 ml pool of fractions 14-17 was finally retrieved in a concentration of 0.2 mg/ml.
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Fig. 4.14. SDS-PAGE gel with both molecular size markers in the first and last well. The controls
here used were the samples of the protein before and after digestion taken before
loading into the HPLC system. The wells corresponding to fractions from 2 to 11
present all the expected band between 40-50 kDa corresponding to the
huDHOase-ELF along with a very close secondary band underneath it. The
6xHisTag + MBP can be seen on wells 14-16 where a band, thicker and lower
than the huDHOase, ran between the 40 and 50 kDa size markers.
4.3.3. Purified huDHOase-ELF after SEC
When size exclusion chromatography was performed in the last step of the purification,
after loading the untagged protein to the Superdex 200 10/300 column, a peak of ab-
sorbance of almost 30 mAU first appeared when the 14-16 fractions were being collec-
ted (Fig. 4.15). According to the manufacturer’s chromatograph test, the eluted samples
between these two fractions are between 35 and 67 kDa in size. Therefore, the pool start-
ing at the growth of the peak and finishing at its decline, that was eluted from fractions
12 to 21, was set apart. The rest of the contaminants, smaller in size, were eluted from
fractions 21 to 33 following the irregular peak depicted in the graph.
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Fig. 4.15. Chromatogram retrieved after SEC. The expected huDHOase-ELF eluted during the
peak at 30 mAU, between fraction 14 and 16. The samples that were obtained from
fractions 21 to 33, and induced irregular peaks of conductivity, were considered
contaminants.
Fig. 4.16. SDS-PAGE gel obtained after performing SEC on the protein. A sample before
injection shows the protein plus other contaminants in the first well. A molecular
size marker separates this well from the fractions obtained by size exclusion
chromatography (from 6 to 33). From 15 to 24 the wells present a visible
band between 40 and 50 kDa equivalent to the purified huDHOase-ELF.
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On Fig. 4.16, the SDS-PAGE gel loaded with the fractions coming from the Superdex
200 10/300 column elutions is shown. As control, a sample of the protein before injection
was run showing the protein plus contaminants and other unwanted residues. From the 15
to 19 fractions wells, 5 easily distinguishable bands can be observed between the 40 and
50 kDa size markers. And, as the bands started fading with the progress of the fractions,
this was considered the sought huDHOase-ELF.
Lastly, the pool from fractions 14 to 21 was concentrated by centrifugation and 1.2
mg/ml huDHOase-ELF was obtained in 60 µl.
4.4. Catalytic activity of huDHOase-ELF
For the forward reaction: CA-asp
pH 5−−−⇀ DHO, wt-huDHOase presented a kcat of 113.5 ±
0.5 min-1 while for huDHOase-ELF kcat=1.7 ± 1.1 min-1. Thus, in this direction, the cata-
lytic rate of the wt-huDHOase is 67 times higher than the one presented by the chimera
huDHOase-ELF.
Fig. 4.17. kcat values for wt-huDHOase and huDHOase-ELF in the forward direction of the
reaction.
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As seen in Fig. 4.18, the absorbance measurements taken by the spectrophotometer
present a positive slope following the progressive production of the product DHO as it
absorbs at 230 nm. While wt-huDHOase presented a distinct and well-defined increase of
absorbance, huDHOase-ELF assays were irregular, showing oscillations in the measure-
ments (e.g. huDHOase-ELF assay 3 on Fig. 4.18b).
(a) Absorbance measurements for 5 min at 230 nm when CA-asp was added
to the wt-huDHOase for the forward reaction to take place.
(b) Absorbance measurements for 5 min at 230 nm when CA-asp was added
to the huDHOase-ELF for the forward reaction to take place.
Fig. 4.18. Graphs representing the increase in the absorbance (measured at 230 nm) when DHO
was being produced by both wt-huDHOase and huDHOase-ELF for five minutes.
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When the last three assays were performed on both wt-huDHOase and huDHOase-
ELF, the spectrophotometer measurements indicated the gradual depletion of DHO as it
was being transformed into the substrate CA-asp, giving negative slopes for both reverse
reactions.
(a) Absorbance measurements for 5 min at 230 nm when DHO was added to
the wt-huDHOase for the reverse reaction to take place.
(b) Absorbance measurements at 230 nm for 5 min when CA-asp was added to
the huDHOase-ELF for the reverse reaction to take place.
Fig. 4.19. Graphs depicting the reverse reaction measured at 230 nm: the consumption of DHO
as CA-asp was being produced by both wt-huDHOase and huDHOase-ELF.
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For the reverse reaction: CA-asp ↽−−−−
pH 8.5
DHO, wt-huDHOase presented a kcat of 181.8
± 13.2 min-1 while for huDHOase-ELF kcat=5.9 ± 0.9 min-1. In this direction, wild type
huDHOase exhibited a 31-fold higher rate in comparison with the mutant, huDHOase-
ELF.
Fig. 4.20. kcat values for wt-huDHOase and huDHOase-ELF in the reverse direction of the
reaction.
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5. DISCUSSION
Advantages and disadvantages behind the cloning approach adopted
The main reason behind the design of a different and atypical protocol for the cloning
of the huDHOase is the plasmid pOPIN-M in which is inserted. As the huDHOase can-
not be expressed alone, but with several elements crucial for its purification: 6xHis tag,
MBP and PreScission site; a novel construction of pOPIN-M with the additional elements
was needed so the cells transfected with the plasmid could also express them. However,
by having the huDHOase sequence in this plasmid, the use of the common mutagenesis
protocols that force the use of other vectors (like the pCRTM-Blunt in the case of the
QuikChange Site-directed Mutagenesis from Agilent used in other published works [11])
is hindered. Therefore, the initial and final application of the Three PCRs Method for the
first and fourth round of mutagenesis, demonstrated to be a robust strategy to extract the
huDHOase sequence from the pOPIN-M-huDHOase vector (1st round) and then insert it
again so the purification elements could be expressed attached to the protein (4th round).
And, at the same time this was done, the Three PCRs Method allowed to conduct cloning
steps with successful products, which is actually noteworthy. In some cases, point muta-
tions are difficult to perform and take several attempts even with standard cloning kits but
here, due to the method chosen, the modification of 13 amino acids was achieved with no
major obstacles.
However, the Three PCRs Method also had its drawbacks. It required many steps,
and all of them dependent on the previous one. Moreover, it can be considered a time
consuming procedure: the preparation and setting of the three PCRs programmed lasted
roughly one hour and a half each, the two agarose gels and the extraction of the DNA
from them took an average of an hour to perform, and any unsuccessful PCR1 or PCR2
forced the repetition of the process all over again.
Furthermore, as seen in Fig. 4.1 and Fig. 4.2, by initially cloning the huDHOase in
several disjointed fragments of reduced size, unwanted amplified products derived from
the reaction. The primers annealed in random complementary sites of the plasmid and
started amplifying sequences that later were visible in agarose gels as thin and blurry
bands of different sizes. This reduced the yield of the PCR reactions, as the primers were
not exclusively dedicated to the amplification of the sought sequence.
Besides the loss in efficiency, cutting the gels for the purification of the DNA also
resulted in a complicated and risky task. Many initial attempts for the 1st round were
unsuccessful due to the obtaining of smeared gels like the one shown in Fig. 4.2b. When
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cutting the gel, some DNA material that did not correspond to the PCR products desired
was also purified and attached into the sequence, turning all the previous work fruitless.
Nevertheless, after the ligation step, the use of the QuikChange Site-directed Muta-
genesis protocol for the second and third rounds resulted in an efficient intermediate
choice of procedure in order to clone the huDHOase in less time while reducing the con-
sumption of reagents and the number of dependent steps.
NaeI, key againsts time and expenditure burn up
Strikingly, the finding of NaeI as the only endonuclease that was able to cut in different
patterns the mutated sequences, coming from each round of mutagenesis, was very fortu-
nate. In this way, Serial Cloner’s Virtual Cutter demonstrated its usefullness by filtering
among the many restriction enzymes that exist in the market to discover the only one that
fit the requirements, NaeI.
Despite the care taken when extracting the DNA from the gels, and the many controls
performed during the transformation of TOP10 cells, the inclusion of a digestion step with
the restriction enzyme NaeI resulted in the most appropriate approach to tackle any false
positive. As a consequence, time and money were spared and the possible candidates
were easily validated for their sending for Sanger sequencing.
Sequencing results of the huDHOase-ELF
When the first three rounds of mutagenesis were retrieved from Sanger sequencing, the
analysis of the chromatograms showed the targeted bases successfully mutated just as ex-
pected, without any insertions or deletions that could cause the alterations of its sequence.
Per contra, on the fourth round, besides the insertion of a histidine and the substitutions of
the next three amino acids, another base was also substituted: g.4695C>T. This base, not
belonging to the target sequence of the primers, was considered an undesirable mutation.
To determine if the base calling33 for this nucleotide was correct, the chromatogram in
Fig. 5.1 was inspected. Clearly, the curve representing the thymine in red has the correct
shape and is exempt of noise [33]. However, to fully assure the legitimacy of this base
read, the quality file also given by Stab Vida was checked.
Out of 60 in the Phred Score (Equation 5.1), this base position scored a 55, meaning
that the probability of being mistakenly read is of 1 in 200,000 base calls [34]. Therefore,
33process done after sequencing in which every peak of the chromatogram is assigned one base
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the silent mutation34 was confirmed.
Q = −10 log10 P (5.1)
Where Q is the quality Phred Score and P is the base-calling error probability.
Fig. 5.1. Chromatogram showing the silent mutation of a cytosine into a thymine (g.4695C>T) in
the huDHOase-ELF sequenced after the fourth round of mutagenesis.
However, thanks to codon degeneracy35, the silent mutation and the two bases next
to it coded for the same amino acid that was looked for during mutagenesis. Moreover,
the abundance of asparagines that are coded by this generated triplet of bases in both
human and E.coli species is 46% with respect to other asparagines translated by other
codons [35], a very high abundance that allowed for the codon sequence to be left off
intact. Therefore, no additional cloning step to reverse the mutation was performed and
the silent mutation remained in the final huDHOase-ELF construct.
PEI as transfection vector for expression of mutant huDHOase-ELF
As shown in Fig. 4.10b, the expression of the GFP plasmid was only present in a small
number of cells, meaning that the PEI ability of creating polyplexes with the DNA was
poor. This can be due to two things:
1. The PEI used was branched, a type of PEI that has shown a remarkable transfection
capacity in many studies in comparison with linear PEI [36] but presents high cyto-
toxic impact [37] which may be a possible explanation for the low number of cells
expressing GFP.
34base substitution that generates a different codon but do not change its corresponding amino acid in
the protein
35phenomenon by which several different codons code for the same amino acid in a protein, the redund-
ancy of the genetic code
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2. The ratio used for the induction of polyplexes was not properly chosen and the
equilibrium of charges between the polymer (positive) and the plasmid (negative)
was not achieved, hampering the cell uptake and endosomal escape36 of the plasmid
for its subsequent expression.
Despite these two possible limitations in the throughput, enough amount of protein
was obtained for the activity assays. Furthermore, the ability of the cells to uptake the
pOPIN-M-huDHOase-ELF plasmid and express it into a protein, presented preliminary
indicia that the protein can be fairly expressed in mammalian cells even with such a major
mutation on its sequence.
huDHOase-ELF and its singular purification
When IMAC was performed, and the histidine tagged huDHOase-ELF bound to MBP
was eluted from the nickel cartridge, standard and recognizable peaks were obtained as
shown in Fig. 4.11, with the addition of a conductivity peak between the ones representing
the contaminants and the protein. This peak, characterized by its oscillatory behaviour, is
an artifact possibly caused by a bubble of air passing through the UV detector.
Aside from this punctual artifact, the HPLC was used again for the separation of the
huDHOase-ELF from the 6xHis Tag + MBP and, once again, ordinary and standard peaks
were retrieved and taken as indicators of the proper sorting of both elements. However,
when the gel with the huDHOase-ELF samples after digestion was checked, a second
band below the expected one (in between the 40 and 50 kDa markers) appeared in wells
2, 5, 7, 9 and 11. There are two hypotheses to explain this unexpected bands in the gel:
1. The SDS-PAGE gel might not have been properly polymerized and the double band
was caused by the discontinuous matrix of the polymer. Nevertheless, this hypo-
thesis is partially discarded as the rest of the bands shown in the gel do not present
a duplication like the one observed in those wells.
2. The bands below may indicate the presence of protein with lower amount of amino
acids and therefore, with lower molecular weight. This may be due to the pos-
sible degradation of the C-terminal extension of the huDHOase-ELF by the pro-
teases used during the purification process. This terminal extension, as described
by Grande-García et al., is a fundamental part for the protein as it is required for
its solubility and it is very sensitive to cleavage [8]. Therefore, it is possible that by
using a non-optimal amount of proteases during its purification, some of the protein
might not have its amino acid sequence intact.
36pH-triggered process by which the polyplexes rupture the membrane of the endosome and are released
into the cytoplasm of the cell
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After this second band was visualized, the purification was continued with special care
for the last size exclusion chromatography step. In this case, it was actually the gel the
one showing ordinary results with unique bands in each well between the 40 and 50 kDa
size markers. When the chromatogram retrieved from the HPLC system was examined,
the peak corresponding to the elution of the protein remained within a range between 35
and 67 kDa, not the expected size of the huDHOase in its dimer conformation. This elu-
tion profile, however, fits better the size of only one subunit of the huDHOase (approx.
42.8 kDa) and implies the behaviour of the protein as a monomer in solution while the
purification took place, an interesting premise taken into account later, in addition to the
hypothesis of the degradation of the C-terminal, when evaluation of the catalytic rate of
the protein was performed.
Moreover, despite the protein being successfully isolated from other components and
properly purified, the yield of this procedure was very low. After concentration of the
protein, only 60 µl were retrieved. A volume that forced to choose between assaying the
protein’s activity or doing crystallization screening to later solve its structure by X-ray
diffraction [8]. Consequently, special care should be taken during future purifications of
the protein, as the loss of protein bound to contaminants, and after concentration, con-
firms its delicate and unstable nature during purification.
Activity assays, considerations on methodology and kinetic results
Before a comparison between the wild type huDHOase and the chimera huDHOase-ELF
can be drawn, the activity coming from the wt-huDHOase assays was compared with the
previous work done about this protein. In the study of huDHOase’s kinetic parameters
done by Grande-García et al., both catalytic constants, kcat = 191.4 ± 2.6 min-1 for the
forward reaction and kcat = 349.8 ± 10.4 min-1 for the reverse direction [8], were higher
than the ones obtained in this project (113.5 ± 0.5 min-1 and 181.8 ± 13.2 min-1 respect-
ively). However, just like in their study, the kcat for the forward reaction presents a lower
value in comparison with the one corresponding to the reverse direction.
There are two possible explanations for the difference between the huDHOase’s kcat
obtained in Grande-García’s et al study and the one here reported.
On the one hand, the wt-huDHOase used in this experiment was frozen and then
thawed repeatedly, as it was used for many past experiments before this project. As a con-
sequence, the temperature changes suffered by the protein might have been detrimental
and could explain the reduction of its activity [38].
On the other hand, another potential reason is the pH at which the activity assays were
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performed, as huDHOase activity is pH dependent [8]. While Grande-García et al. used a
pH of 5.5 and 8 for the forward and reverse direction respectively, in this project a pH of
5 and 8.5 were employed, as both the wild type and mutant proteins needed to be tested
at the same pH and going into the ones used for maximum catalytic activity could have a
deleterious effect on the mutant.
While other colorimetric and radioactive methods employed to detect the formation
of CA-asp [39], or both directions of the reaction [40], are considered more sensitive and
appropriate for activity assays, other works have reported how all of them showed sim-
ilar results in the determination of huDHOase kcat [41]. Due to this fact, the triplicate
detection of DHO formation/consumption in each assay was chosen and with that, many
sources of error or strenuous steps were avoided. However, to guarantee the validity of
the results obtained with this implemented method, there are two aspects that were taken
into account: (1) in addition to the pipetting error (2%), the spectrophotometer used has
1% of random error in its absorbance detection; (2) the linear response of the absorbance
of DHO remains between the 0-54 mM range. To counteract both, assays were done in
triplicates and the concentration of protein and substrate added to the reaction were ad-
justed so no saturation of the detector could occur.
However, as many elements in the sample, apart from tryptophan, present absorbance
at 230 nm (Tris Buffer, DHOase, EDTA, etc.), it must be taken into account that the pro-
duction/consumption of DHO was not the exclusive measure at each time point and that
chemical noise might have affected the data [42].
The implications behind huDHOase-ELF’s activity results
As seen in Fig. 4.18a and Fig. 4.19a, the spectrophotometer provided the expected meas-
ures of absorbance when the wild type huDHOase produced or consumed DHO respect-
ively. In the case of the readings for the mutant huDHOase-ELF, with the exception of
assay 3 in the forward reaction (Fig. 4.18b), the fluctuations in the measures were minimal
and the slope of the graphs from both directions manifest the, however small, activity of
the protein.
Indeed, as presented in Fig. 4.17 and Fig. 4.20, parted y axis were needed to represent
the negligible activity of the huDHOase-ELF next to the wt-huDHOase. With a 67-fold
difference in the forward direction and 31 in the reverse direction, the chimera developed
does not hold the same catalytic activity exhibited by the wild type. Nonetheless, the
slopes calculated in all six essays performed on the mutant all gave different values from
zero, demonstrating that although small, the ability to transform the substrate CA-asp into
the product (Fig. 4.18b) and vice versa (Fig. 4.19b) remained. The main reason account-
able for this dramatic decrease in the activity is, as expected, the considerable mutation
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performed to the sequence and its effects on the movement mechanism of the flexible loop.
However, before elaborating into this assumption, two important consideration must be
taken into account:
• As discussed previously, the C-terminal extension of the protein might have suffered
a cleavage during purification, which could be translated into structural and prop-
erty changes that affected its catalytic activity besides the interchange of flexible
loop with ecDHOase conducted.
• After size exclusion chromatography, the protein eluted in fractions correspond-
ing to a given size range but its exact molar mass was not determined as for that,
MALS37 (Multi-Angle Light Scattering) should be coupled to the HPLC system
after size exclusion chromatography. Therefore, as the protein was not confirmed
to be a dimer, it is possible that the first amino acid mutations in the flexible loop not
only affected the mechanism of catalysis of the enzyme but its ability to oligomer-
ize38. And, as the estimated loss of activity when huDHOase is in monomer con-
formation (according to work pending for publication under the name of Ramón-
Maiques) is half the activity the dimer presents, it should be taken into account
when examining the kinetic data.
Despite the fact these two preliminary remarks could not be examined further with
the data obtained during the project, the catalytic activity of the chimeric huDHOase-ELF
was so tremendously affected that both considerations are not enough to justify it. There-
fore, the mutation of the human flexible loop into the E.coli sequence can be described as
the major responsible for this decrease in activity.
As seen in Fig. 4.17, with a 67-fold decrease in activity for the forward reaction, the
chimeric huDHOase-ELF demonstrates that the flexible loop in humans is irreplaceable.
Despite having some similarities with E.coli’s catalytic mechanism, both huDHOase-ELF
kcat here reported prove that the change in amino acid sequence can alter the mechanical
and catalytic behavior of the loop.
An important detail regarding this sequence identity involves the residue Thr109 in
ecDHOase and its equivalent in huDHOase, Thr1562. This threonine, positioned at the
tip of the loop, is reported to be a key interacting element with inhibitor molecules and
the substrate, forming a hydrogen bond with CA-asp in E.coli [13] and humans [8]. This
hydrogen bond would allow the proper confinement of the substrate into the active site
favoring and providing stability to the catalytic reaction while avoiding unwanted inter-
actions [12]. As this function seems important for the catalysis, many species have this
threonine conserved (E.coli, Homo Sapiens, P.gingivalis etc.) but, as demonstrated with
37technique employed for the precise measurement of molar mass and characterization of oligomers
38process in which a protein assembles into oligomers by the polymerization of its monomer constituents
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the activity of huDHOase-ELF obtained, even if the residue is left intact, insertions and
mutations may disorder the loop, inducing steric clashes that could hinder the reactions
between the atoms in the active site and this threonine to take place.
Several other relationships between the flexible loop and the elements of the protein
can also be speculated to end up affected. As explained on Section 1.1, if the mutation
of the flexible loop or the residues in charge of the dimer interface caused the change of
the movement mechanism, then the communication between subunits might have been
hampered and the cooperativity39 between subunits impaired [12]. On the other side, if
the bridging ligands between the metal cations were displaced, the whole arrangement of
the active site might have been altered, with the consequences that would entails.
Nonetheless, both hypotheses on the lack of stabilization of the flexible loop into its
IN conformation while sequestering the substrate/inhibitor, and the alteration of its spatial
configuration, need to be examined once the 3D structure of the protein is solved as for
now the data obtained only provided with the possibility of speculation.
Finally, with the catalytic activity reported for this mutant, it is somehow demonstrated
that, even with similar sequences, the flexible loop from one DHOase species cannot be
substituted with another loop from other species. Other elements, apart from the loop’s
residues, are actively participating into the catalysis and their interactions with the loop
are crucial for its mechanism.
39change of shape and affinity of a protein subunit when a ligand binds to the active site of other of its
subunits
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6. CONCLUSIONS AND FUTURE WORK
With the experiments performed during the work here presented, the design of a feas-
ible and robust cloning method for the mutation of huDHOase flexible loop into a new
sequence of 13 amino acids coming from E.coli was achieved. By using a combination
of The Three PCRs Method and QuikChange Site-directed Mutagenesis, it was possible
to create a chimera between both species with additional features in its structure for its
efficient purification during the implementation of chromatography techniques as IMAC
and SEC [15].
Nonetheless, experiments must continue, as the huDHOase-ELF obtained by expres-
sion of the plasmid on mammalian cells presented an unstable nature during purification
and its characteristics as monomer or dimer, as well as the integrity of its complete se-
quence, were unable to be described with the experiments performed and the data re-
trieved. Due to this, expression using induction instead of transfection, and the use of
IMAC followed by coupling MALS to the size exclusion chromatography technique, must
be performed. These two different approaches in the expression and purification strategy
might help to answer if the reduced amount of protein obtained was caused by the inef-
ficiency of PEI as transfection vector, or if its unstable behaviour and its monomer-like
elution profile during purification was caused by an alteration of its structure. There-
fore, the molar mass of the protein must be first described by MALS and, after that, the
mutations conducted must be inspected in case they affected to the oligomerization of the
protein.
But, most importantly, the overall behaviour of the protein is clearly altered and the
experiments here described point at the loop as the main suspect responsible the changes
observed on its solubility and oligomer formation. Interestingly, the negligible activity
shown by the chimera huDHOase-ELF availed the statements pointing at the flexible loop
as a crucial element for solubility and oligomer stability of the protein and, at the same
time, as the main structure behind the huDHOase catalysis. This flexible loop might be
so exclusive for each species that, even with similar movement and catalytic mechanism,
the sequence of amino acids is so refined for each species that the studies previously done
on E.coli DHOase do not provide with enough knowledge that could be extrapolated to
human. In the case, for example, of the Plasmodium parasite responsible for malaria, this
would imply the possibility of designing species-specific inhibitors that affect only the
DHOase of interest, as DHOases might share similar catalytic behaviour but with major
differences in its mechanical/biochemical mechanism.
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Moved by the referred specificity of the flexible loop mechanism, crystallization screen-
ing is planned to be performed in order to solve the conformation of the chimera huDHOase-
ELF by X-ray crystallography in the near future [43]. With the three-dimensional struc-
ture given by this technique, interesting data could be extracted from the arrangement of
its binding pocket [15] and models of the loop’s movement could explain more specific-
ally its interactions with other elements in the protein.
Furthermore, once the behaviour of this chimera is incorporated to the previous know-
ledge compiled from other mutants, some clues on huDHOase crucial elements could
be derived aiding in the search for robust cytotoxic inhibitors. These inhibitors, acting
as cytotoxic agents targeting DHOases by resilient interactions and halting its catalytic
mechanism, could become potential therapeutic tools in the future battle against cancer
cells or parasites as Plasmodium.
Finally, as this work will be presented shortly as part of the 26th International Confer-
ence on Arginine and Pyrimidines and the 1st International Conference on Amino Acids
and Nucleotides (ICAP | ICAN2018) at ShanghaiTech University, it is expected that the
discussion over the project will enlighten the results obtained and new approaches in the
methodology might be suggested.
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7. SOCIO-ECONOMIC IMPACT
7.1. Analysis of the project’s envisioned repercussions
In the case of the work here presented, with the crystallographic analysis of the synthes-
ized huDHOase-ELF that will be continued after the catalytic results obtained, three main
spheres might suffer an impact in a domino effect manner:
Academia, field impact.
The methodology followed for the obtaining of the mutant huDHOase, as well as
the activity results preceding the crystallographic work, represent key elements in the
knowledge contribution this work is providing to the scientific community. The better un-
derstanding of pyrimidine biosynthesis might encourage others to research on other CAD
domains or the metabolic alteration cells suffer in this metabolic pathway when turned
neoplastic.
The impact on the economy of drug development and drug efficiency.
With the knowledge acquired, and the confidence of the results, pharmacological com-
panies might find the prospect of designing an inhibitor against huDHOase attractive.
However, how different can the huDHOase-ELF make the drug market? By the through-
out and careful study of the target, better synthetic compounds can be designed. And
this, as basic as it may appear, makes a real difference. Current studies show how 90%
of antitumoral drugs, even in combination with other therapies like chemotherapy and
radiotherapy, fail to pass the so-called Valley of Death [44], the stage in which most of
the drugs are unapproved due to its effectiveness and unsatisfactory results. And, to bring
those drugs to the edge of the valley even before they fall, pharma companies spend 1.55
billion of dollars [45]. Due to the risk that drug development entails, and the high mon-
etary losses pharma companies face, only by providing them with a feasible and credible
venture proposal, investments on experimental drugs that cross the Valley could achieve
success.
Furthermore, by a sensible combination between this potential drug and other anti-
cancer treatments, a proper use of healthcare resources would be executed, decreasing the
costs public healthcare system abide on useless and hopeless treatments.
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Patients, the human impact
And finally, and most importantly, this study could ultimately have an impact on hu-
man lives. A more careful study on the target would produce a more efficient inhibitor
that, in a particular combination with other treatments, would provide cancer patients with
a personalized approach in the battle against the disease. This, in fact, means an intangible
impact on the patients regarding two aspects:
• The lessening on their distress and shortening of the suffering due to current strenu-
ous treatments. With the discovery of better targets, the misuse of cytotoxic treat-
ments like chemotherapy and radiotherapy would be overcame, and the pain caused
by the adverse effects related to them could be avoided.
• Personalized medicine and increased expectations on the treatment. By analyzing
the patient prospect and their needs, the combination of traditional treatments with
enzyme inhibitors like PALA or inhibitors designed against huDHOase, could aid
in the implementation of personalized medicine and the confidence on a good result
would help in the psychological battle against the disease. This, as pointless as it
might sound, can also make a difference in the way patients confront their state.
7.2. Estimated budget of the project
The estimated budget for the accomplishment of the project presented can be divided in
three sections. First, the approximate expenditure on common fungible consumables and
reagents followed by the working hours carried out by both the student and supervisor tu-
tor, and lastly a detailed list on the indispensable elements needed to replicate the cloning,
expression and purification of the protein.
An aspect to take into account is the use of free software and student licenses for all
the programs used in this project: Serial Cloner (Freeware), 4peaks (Freeware), PyMOL
(academic license); except for Prism. GraphPad Prism was provided by the CBMSO
laboratory where the project was done and which cost (170 €) is included in Table 7.1.
Description
Estimated net
expenditure per month (€)
Number of
Months
Total Cost (€)
Fungible goods (pipettes, tubes,
eppendorfs, buffers etc.) software
and equipment of the laboratory
700 5 3500
TABLE 7.1. ESTIMATED NET COST OF FUNGIBLE GOODS AND
EQUIPMENT DURING THE MONTHS THE PROJECT LASTED
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Category Hours Gross Cost Per Hour (€) Total Cost (€)
Biomedical engineer 620 10 8680
Research Investigator 70 15 1050
TABLE 7.2. ESTIMATED GROSS COST OF WORKING HOURS
Description Units Cost per unit (€) Total cost (€)
pOPINM-M-huDHOase (Addgene) 1 94.5 95.4
NEB Buffer 10X (New England Biolabs) 1 18.8 18.8
BSA (New England Biolabs) 1 24.9 24.9
HindIII (New England Biolabs) 10,000 units 1 31.8 31.8
KpnI (New England Biolabs) 4,000 units 1 36.1 36.1
Primers (Sigma) 10 5.94 59.4
dNTPs (Thermo Fisher) 4x 250 µl 1 254 254
Phusion 2000 units/ml
Buffer Phusion 5X
DMSO (New England Biolabs)
1 91.8 91.8
Agarose (CONDA) 1 42 42
GelRed (Biotium) 1 85.75 85.75
QIAquick Gel Extraction Kit 50 rxns (Qiagen) 1 101.2 101.2
GeneJET Plasmid Miniprep Kit (Thermo Fisher) 1 62.75 62.75
In-Fusion HD (Clontech) 1 198.17 198.17
Expand Long System Polymerase
Buffer Expand Long 10X (Sigma)
1 145 145
QuikChange Kit (Agilent) 1 355 355
One Shot TOP10 E.coli competent cells (Thermo
Fisher)
1 548 548
NaeI (New England Biolabs) 1 33.55 33.55
Sanger sequencing (Stab Vida) 4 3.5 14
HEK293S-GnTI (ATCC) 1 590 590
Freestyle medium (Gibco) 1 166 166
Polyethylenimine (Sigma) 1 86.5 86.5
UltraDOMA medium (Lonza) 1 26.25 26.25
pCMV-GFP Addgene 1 55.75 55.75
Nickel Cartridge (ABT) AF6Ni-Ctg5-1 1 97.8 97.8
PreScission protease (GE Healthcare) 500 u 1 278.76 278.76
Amicon Ultra filters system (Sigma) 5kDa 1 49.5 49.5
Amicon Ultra filters system (Sigma)10 kDa 1 107 107
Superdex 200 10/300
column was used (GE Healthcare)
1 1474 1474
Acrylamide (Sigma) Powder 100 g 1 58 58
SDS 10% H2O (Sigma) 1 39.75 39.75
TABLE 7.3. DETAILED LIST OF INDISPENSABLE REAGENTS
USED AND THEIR NET COST
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Description Total Cost (€)
Fungible consumables and
equipment of the laboratory
3500
Working Hours 9730
Indispensable Reagents 5226.93
IVA (21%) 1832.65
TOTAL 20289.58
TABLE 7.4. FINAL ESTIMATED BUDGET OF THE PROJECT
69
BIBLIOGRAPHY
[1] D. L. Nelson and M. M. Cox, Principles of Biochemistry, 9. 2013, vol. 53, pp. 1689–
1699, isbn: 9788578110796. doi: 10.1017/CBO9781107415324.004.
[2] Z. Martins et al., “Extraterrestrial nucleobases in the Murchison meteorite”, Earth
and Planetary Science Letters, vol. 270, no. 1-2, pp. 130–136, 2008, issn: 0012821X.
doi: 10.1016/j.epsl.2008.03.026.
[3] J. Koch et al., “CAD mutations and uridine-responsive epileptic encephalopathy”,
Brain, vol. 140, no. 2, pp. 279–286, 2017, issn: 14602156. doi: 10.1093/brain/
aww300.
[4] F. D. Sigoillot, J. A. Berkowski, S. M. Sigoillot, D. H. Kotsis and H. I. Guy,
“Cell cycle-dependent regulation of pyrimidine biosynthesis”, Journal of Biolo-
gical Chemistry, vol. 278, no. 5, pp. 3403–3409, 2003, issn: 00219258. doi: 10.
1074/jbc.M211078200.
[5] D. R. Evans and H. I. Guy, “Mammalian pyrimidine biosynthesis: Fresh insights
into an ancient pathway”, Journal of Biological Chemistry, vol. 279, no. 32, pp. 33 035–
33 038, 2004, issn: 00219258. doi: 10.1074/jbc.R400007200.
[6] M. Moreno-Morcillo et al., “Structural Insight into the Core of CAD, the Multi-
functional Protein Leading De Novo Pyrimidine Biosynthesis”, Structure, vol. 25,
no. 6, 912–923.e5, 2017, issn: 18784186. doi: 10.1016/j.str.2017.04.
012.
[7] G. R. Stark and P. A. Bartlett, “Design and use of potent, specific enzyme inhib-
itors”, Pharmacol Ther, vol. 23, no. 1, pp. 45–78, 1983. doi: 0163-7258(83)
90026- 8[pii]. [Online]. Available: http://www.ncbi.nlm.nih.
gov/entrez/query.fcgi?cmd=Retrieve%7B%5C&%7Ddb=PubMed%
7B%5C&%7Ddopt=Citation%7B%5C&%7Dlist%7B%5C_%7Duids=
6361807.
[8] A. Grande-García, N. Lallous, C. Díaz-Tejada and S. Ramón-Maiques, “Structure,
functional characterization, and evolution of the dihydroorotase domain of human
CAD”, Structure, vol. 22, no. 2, pp. 185–198, 2014, issn: 09692126. doi: 10.
1016/j.str.2013.10.016.
[9] B. G. Ng et al., “Biallelic mutations in CAD, impair de novo pyrimidine biosyn-
thesis and decrease glycosylation precursors”, Human Molecular Genetics, vol. 24,
no. 11, pp. 3050–3057, 2014, issn: 14602083. doi: 10.1093/hmg/ddv057.
70
[10] J. B. Thoden, G. N. Phillips, T. M. Neal, F. M. Raushel and H. M. Holden, “Mo-
lecular structure of dihydroorotase: a paradigm for catalysis through the use of a
binuclear metal center.”, Biochemistry, vol. 40, no. 24, pp. 6989–6997, 2001, issn:
0006-2960. doi: 10.1021/bi010682i.
[11] M. Lee, M. J. Maher, R. I. Christopherson and J. M. Guss, “Kinetic and struc-
tural analysis of mutant Escherichia coli dihydroorotases: A flexible loop stabilizes
the transition state”, Biochemistry, vol. 46, no. 37, pp. 10 538–10 550, 2007. doi:
Doi10.1021/Bi701098e.
[12] M. Lee, C. W. Chan, J. M. Guss, R. I. Christopherson and M. J. Maher, “Di-
hydroorotase from Escherichia coli: Loop movement and cooperativity between
subunits”, Journal of Molecular Biology, vol. 348, no. 3, pp. 523–533, 2005, issn:
00222836. doi: 10.1016/j.jmb.2005.01.067.
[13] M. Lee et al., “Structures of Ligand-free and Inhibitor Complexes of Dihydroorotase
from Escherichia coli: Implications for Loop Movement in Inhibitor Design”, Journal
of Molecular Biology, vol. 370, no. 5, pp. 812–825, 2007, issn: 00222836. doi:
10.1016/j.jmb.2007.05.019.
[14] R. I. Christopherson and M. E. Jones, “Interconversion of carbamayl-L-aspartate
and L-dihydroorotate by dihydroorotase from mouse Ehrlich ascites carcinoma.”,
The Journal of biological chemistry, vol. 254, no. 24, pp. 12 506–12 512, 1979,
issn: 0021-9258. [Online]. Available: http://www.jbc.org/content/
254/24/12506.short%7B%5C%%7D5Cnpapers2://publication/
uuid/B8B08B95-48E4-4EFB-90B9-D4DB68657E31.
[15] A. Ruiz-Ramos, N. Lallous, A. Grande-García and S. Ramón-Maiques, “Expres-
sion, purification, crystallization and preliminary X-ray diffraction analysis of the
aspartate transcarbamoylase domain of human CAD”, Acta Crystallographica Sec-
tion F: Structural Biology and Crystallization Communications, vol. 69, no. 12,
pp. 1425–1430, 2013, issn: 17443091. doi: 10.1107/S1744309113031114.
[16] D. Roy, G. J. Steyer, M. Gargesha, M. E. Stone and L. Wilson, “Design, syn-
thesis and bioactivity of novel inhibitors of E. coli aspartate transcarbamoylase”,
in Bioorganic & medicinal chemistry letters, 7, vol. 17, 2007, pp. 2086–2090, isbn:
0130149616. doi: 10.1016/j.bmcl.2006.12.050.
[17] J. L. Grem, S. A. King, P. J. O’Dwyer and B. Leyland-Jones, “Biochemistry and
clinical activity of N-(phosphonacetyl)-L-aspartate: a review.”, Cancer research,
vol. 48, no. 16, pp. 4441–4454, 1988, issn: 00085472. [Online]. Available: http:
//eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?
dbfrom=pubmed%7B%5C&%7Did=3293772%7B%5C&%7Dretmode=
ref%7B%5C&%7Dcmd=prlinks%7B%5C%%7D5Cnpapers2://publication/
uuid/C2308983-E9D9-46EE-95BB-4BED1ABD9577.
71
[18] K. K. Tsuboi, H. N. Edmunds and L. K. Kwong, “Selective Inhibition of Pyrimidine
Biosynthesis Proliferative Growth of Colonie Cancer Cells1”, Cancer Research,
vol. 37, no. September, pp. 3080–3087, 1977.
[19] M. Lee et al., “Structures of Ligand-free and Inhibitor Complexes of Dihydroorotase
from Escherichia coli: Implications for Loop Movement in Inhibitor Design”, Journal
of Molecular Biology, vol. 370, no. 5, pp. 812–825, 2007, issn: 00222836. doi:
10.1016/j.jmb.2007.05.019.
[20] Z. M. Gomez and P. K. Rathod, “Antimalarial activity of a combination of 5-
fluoroorotate and uridine in mice”, Antimicrobial Agents and Chemotherapy, vol. 34,
no. 7, pp. 1371–1375, 1990, issn: 00664804. doi: 10.1128/AAC.34.7.1371.
[21] R. I. Christopherson et al., “Mercaptan and dicarboxylate inhibitors of hamster
dihydroorotase”, Biochemistry, vol. 28, no. 2, pp. 463–470, 1989, PMID: 2565732.
doi: 10.1021/bi00428a009. [Online]. Available: https://doi.org/
10.1021/bi00428a009.
[22] J. Brooke et al., “Cytotoxic Effects of Dihydroorotase Inhibitors upon Human
CCRF-CEM Leukemia”, Cancer Research, vol. 50, no. 24, pp. 7793–7798, 1990,
issn: 15387445.
[23] V. Revadigar et al., “Enzyme Inhibitors Involved in the Treatment of Alzheimer’s
Disease”, in Drug Design and Discovery in Alzheimer’s Disease, Elsevier, 2014,
pp. 142–198, isbn: 9780128039595. doi: 10.1016/B978-0-12-803959-
5.50003-9. [Online]. Available: http://linkinghub.elsevier.com/
retrieve/pii/B9780128039595500039.
[24] V. Chopra et al., “The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington’s
disease mouse models.”, Cell reports, vol. 2, no. 6, pp. 1492–7, Dec. 2012, issn:
2211-1247. doi: 10.1016/j.celrep.2012.11.001. [Online]. Available:
http://www.ncbi.nlm.nih.gov/pubmed/23200855%20http:
//www.pubmedcentral.nih.gov/articlerender.fcgi?artid=
PMC3534897.
[25] H. K. Weir et al., “Heart Disease and Cancer Deaths — Trends and Projections in
the United States, 1969–2020”, Preventing Chronic Disease, vol. 13, p. 160 211,
2016, issn: 1545-1151. doi: 10.5888/pcd13.160211. [Online]. Available:
http://www.cdc.gov/pcd/issues/2016/16%7B%5C_%7D0211.
htm.
[26] N. Hamajima, T. Saito, K. Matsuo and K. Tajima, “Competitive amplification and
unspecific amplification in polymerase chain reaction with confronting two-pair
primers”, Journal of Molecular Diagnostics, vol. 4, no. 2, pp. 103–107, 2002, issn:
15251578. doi: 10.1016/S1525-1578(10)60688-5.
72
[27] P. Y. Lee, J. Costumbrado, C.-Y. Hsu and Y. H. Kim, “Agarose Gel Electrophoresis
for the Separation of DNA Fragments”, Journal of Visualized Experiments, no. 62,
pp. 1–5, 2012, issn: 1940-087X. doi: 10.3791/3923. [Online]. Available: http:
//www.jove.com/video/3923/.
[28] P. a. Longo, J. M. Kavran, M.-s. Kim and D. J. Leahy, “Transient Mammalian Cell
Transfection wtih Polyethylenimine”, Methods Enzymology, vol. 529, pp. 227–240,
2014. doi: 10.1016/B978-0-12-418687-3.00018-5.Transient.
[29] K. Weber and M. Osborn, “The Reliability of Molecular Weight Determinations
Sulf ate-Polyacrylamide Gel Electrophoresis”, The Journal of Biological Chem-
istry, vol. 244, no. 16, pp. 4406–4412, 1969, issn: 0021-9258, 1083-351X. [On-
line]. Available: http://www.jbc.org/content/244/16/4406.
short.
[30] M. M. Bradford, “A rapid and sensitive method for quantification of microgram
quantities of protein utilizing the principle of dye-binding”, Anal. Biochem., vol. 72,
pp. 248–254, 1976.
[31] E. G. Sander, L. D. Wright and D. B. McCormick, “Evidence for function of
a metal ion in the activity of dihydroorotase from Zymobacterium oroticum.”,
The Journal of biological chemistry, vol. 240, no. 9, pp. 3628–3630, 1965, issn:
00219258.
[32] D. F. Swinehart, “The Beer-Lambert Law”, Journal of Chemical Education, vol. 39,
no. 7, p. 333, 1962, issn: 0021-9584. doi: 10.1021/ed039p333. [Online].
Available: http://pubs.acs.org/doi/abs/10.1021/ed039p333.
[33] P. Cliften, “Chapter 7 - base calling, read mapping, and coverage analysis”, in Clin-
ical Genomics, S. Kulkarni and J. Pfeifer, Eds., Boston: Academic Press, 2015,
pp. 91–107, isbn: 978-0-12-404748-8. doi: https://doi.org/10.1016/
B978-0-12-404748-8.00007-1. [Online]. Available: https://www.
sciencedirect.com/science/article/pii/B9780124047488000071.
[34] C. Ledergerber and C. Dessimoz, “Base-calling for next-generation sequencing
platforms”, Briefings in Bioinformatics, vol. 12, no. 5, pp. 489–497, 2011, issn:
14675463. doi: 10.1093/bib/bbq077.
[35] J. Athey et al., “A new and updated resource for codon usage tables”, BMC Bioin-
formatics, vol. 18, no. 1, pp. 1–10, 2017, issn: 14712105. doi: 10.1186/s12859-
017-1793-7.
[36] A. Bragonzi et al., “Comparison between cationic polymers and lipids in mediating
systemic gene delivery to the lungs”, Gene Therapy, vol. 6, no. 12, pp. 1995–2004,
1999, issn: 09697128. doi: 10.1038/sj.gt.3301039.
[37] K. V and O. Y, “Cytotoxic Impacts of Linear and Branched Polyethylenimine
Nanostructures in A431 Cells”, BioImpacts, vol. 1, no. 1, pp. 23–30, Jan. 2017.
doi: 10.5681/BI.2011.004. [Online]. Available: http://bi.tbzmed.
ac.ir/Abstract/BI%7B%5C_%7D20120818132636.
73
[38] R. M. Daniel and M. J. Danson, “Temperature and the catalytic activity of enzymes:
A fresh understanding”, FEBS Letters, vol. 587, no. 17, pp. 2738–2743, 2013, issn:
00145793. doi: 10.1016/j.febslet.2013.06.027. [Online]. Available:
http://dx.doi.org/10.1016/j.febslet.2013.06.027.
[39] L. M. Prescott and M. E. Jones, “Modified methods for the determination of car-
bamyl aspartate”, Analytical Biochemistry, vol. 32, no. 3, pp. 408–419, 1969, issn:
10960309. doi: 10.1016/S0003-2697(69)80008-4.
[40] R. Christopherson, T. Matsuura and M. Jones, “Radioassay of dihydroorotase util-
izing ion-exchange chromatography”, Analytical biochemistry, vol. 89, no. 1, pp. 225–
234, Aug. 1978, issn: 0003-2697. doi: 10.1016/0003-2697(78)90745-5.
[Online]. Available: https://doi.org/10.1016/0003- 2697(78)
90745-5.
[41] R. Alba, G. Araceli and R. Santiago, “Dihydroorotase domain of human cad”, in
Encyclopedia of Inorganic and Bioinorganic Chemistry. American Cancer Soci-
ety, 2015, pp. 1–16, isbn: 9781119951438. doi: 10.1002/9781119951438.
eibc2321. [Online]. Available: https://onlinelibrary.wiley.com/
doi/abs/10.1002/9781119951438.eibc2321.
[42] P. F. Liu, L. V. Avramova and C. Park, “Revisiting absorbance at 230 nm as a pro-
tein unfolding probe”, Analytical Biochemistry, vol. 389, no. 2, pp. 165–170, 2009,
issn: 00032697. doi: 10.1016/j.ab.2009.03.028. [Online]. Available:
http://dx.doi.org/10.1016/j.ab.2009.03.028.
[43] E. Ennifar, “X-ray Crystallography as a Tool for Mechanism-of-Action Studies and
Drug Discovery”, Current Pharmaceutical Biotechnology, vol. 14, no. 5, pp. 537–
550, Nov. 2013, issn: 13892010. doi: 10.2174/138920101405131111104824.
[Online]. Available: http://www.eurekaselect.com/openurl/content.
php?genre=article%7B%5C&%7Dissn=1389-2010%7B%5C&%7Dvolume=
14%7B%5C&%7Dissue=5%7B%5C&%7Dspage=537.
[44] D. J. Adams, “The valley of death in anticancer drug development: A re-assessment”,
Trends in Pharmacological Science, vol. 33, no. 4, pp. 173–180, 2012. doi: 10.
1016/j.tips.2012.02.001.The.
[45] M. Hay, D. W. Thomas, J. L. Craighead, C. Economides and J. Rosenthal, “Clin-
ical development success rates for investigational drugs”, Nature Biotechnology,
vol. 32, p. 40, Jan. 2014. [Online]. Available: http://dx.doi.org/10.
1038/nbt.2786%20http://10.0.4.14/nbt.2786%20https://
www.nature.com/articles/nbt.2786%7B%5C#%7Dsupplementary-
information.
74
